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CHAPTER 1 
INTRODUCTION 
INTRODUCTION 
Many processes in health and disease represent the interaction between host 
(endogenous) and environmental (exogenous) factors. In this interplay, genet-
ic factors play a major role. An important example of host interaction with 
exogenous factors in medicine is the patient's reaction to drug treatment. In 
this respect many data exist on drug toxicity, clinical response, and pharma-
cokinetics. However, the study of the influence of genetical factors on drug 
effects is still in its infancy, as indicated by the scarce data available. 
The present thesis reports studies aimed to detect genetical factors in drug 
response by correlating HLA phenotypes with the way patients with rheumatoid 
arthritis react to so-called second line drugs, a corner stone in the treat-
ment of this disease. Before presenting the aim of the study in more detail, 
we would like to present in brief some relevant data: 
- on the clinical syndrome rheumatoid arthritis 
- on its therapy 
- on how patients react to second line drugs in terms of effect and side ef-
fects 
- on what was known about the genetics of both rheumatoid arthritis and reac-
tion to second line drugs, at the moment this study started. 
Rheinatoid arthritis: clinical features 
Rheumatoid arthritis is a chronic systemic inflammatory disorder of unknown 
etiology characterized by the manner in which it involves joints. In addition 
to arthritis, which is often polyarticular and symmetrical, there are extra 
articular manifestations, of which the rheumatoid nodule is the best known 
example (1). General symptoms include fatigue, malaise, weakness and general 
aching and stiffness in part of the patients. Laboratory features 
include the presence of rheumatoid factors in the serum, anaemia and elevated 
sedimentation rate, the latter two abnormalities reflecting disease activi-
ty. The course of the disease is variable and capricious, ranging from epi-
sodes of polyarthritis, alternated by spontaneous remissions to a (rapidly) 
progressive arthritis, sometimes with widespread systemic features (2). This 
stresses the need for controlled observations in studies on rheumatoid arthr-
itis (3). The prognosis in terms of validity is largely determined by joint 
involvement, the latter being largely dependent on the degree and rapidity of 
onset of destructive lesions in the joint and periarticular structures. 
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Treatment of rheinatoid arthritis 
The plan of treatment may be considered under two headings. Firstly, treat-
ment modalities concerning modification of the patient, including rest, 
drugs, physical therapy and surgery; and secondly, there may be a need for 
modification of the environment in terms of appliances, housing, occupation 
and transportation. It may appear from this compilation, that many discipli-
nes can be involved in the treatment of a patient with rheumatoid arthritis. 
As far as drug treatment is concerned, several groups of drugs can be used. 
If pain is the only symptom, while no signs of inflammatory activity are pre-
sent, simple analgesics may be used. In case of significant inflammatory ac-
tivity, one or more of the following categories should be considered: 
- non-steroidal anti-inflammatory drugs: e.g. salicylates, indomethacine, na-
proxen. These drugs give relief of pain and short term suppression of in-
flammation. They do not essentially alter the natural history of the dis-
ease. 
- second line drugs: antimalarials (chloroquine compounds), gold salts, d-pe-
mcillamine and immunosuppressive drugs. These drugs possess the potency to 
induce a remission. Disadvantages of this category include thehigh inciden-
ce of toxicity, the delayed action (these drugs do not work until 2 to 3 
months after institution of the therapy) and the fact that a number of pa-
tients do not respond to the treatment. 
- Low dose steroids: this treatment is given when the above antirheumatic 
drugs are insufficiently effective or cause side-effects. 
Gold salts and d-penicillanine 
a. Preparation and dosage. 
Gold salts are available in the form of parenteral gold and recently also 
of oral gold. The parenteral form, used in the Netherlands and therefore 
in our studies, is aurothioglucose (AuTG), a water soluble suspension in 
oil. The dose scheme generally used, is 50 mg AuTG per intramuscular in-
jection per week during 20 weeks, after which the dose is reduced gradual-
ly. Laboratory controls include peripheral blood leucocyte count and dif-
ferential, thrombocyte count and urinalysis for protein before each injec-
tion. 
D-pemcillamine (DP) is started in a daily dose of 250 mg according to the 
go low-go slow principle (4). If this dose is ineffective, monthly incre-
ments of 125 to 250 mg up to a maximal daily dose of 750 mg are given. 
Toxicity controls are essentially the same as for AuTG and are done weekly 
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in the first months. If an effective maintenance dose is reached, interval 
between controls for toxicity can be decreased to once per three to four 
weeks. 
Efficacy. 
Both drugs are generally not effective before three months of treatment, 
so that evaluation of efficacy before that period is not useful. Parame-
ters to assess disease activity are manyfold. They can be divided into 
subjective ones, e.g. morning stiffness and pain; semi-objective parame-
ters, e.g. joint tenderness and grip strength and objective ones such as 
erythrocyte sedimentation rate (ESR) and hemoglobin. These parameters can 
be used separately or as part of an index like those advocated by Mallya 
et al (5) or Van Riel (6). By quantitating the parameters and therefore 
the indices one can define the degree of response during therapy. 
Toxicity. 
Frequencies of toxicity during gold salts and DP therapy are given in ta-
ble I. Most of the side effects occur during the first 6 months. It should 
be stressed that toxicity on gold, not necessarily predisposes the patient 
for (the same) toxicity on DP (7,8) (see Table II). This is relevant be-
cause DP is usually given after gold salt treatment. Several studies 
have indicated particular risk factors for the development of side effects 
on gold salts or DP (see table II). Since DP is also used for other indi-
cations, it became clear that rheumatoid arthritis perse is a risk factor 
leading to more frequent side effects. For gold salts similar data are 
not available. 
TABLE I. Incidence of side effects on intramuscular gold and d-pemcilla-
mine in patients with rheumatoid arthritis. 
type of reaction gold salts (24) d-pemcillamine (25) 
all reactions 
mucocutaneous 
proteinuria 
leucopema 
and 
thrombocytopenia 
rare toxic reactions 
20 - 39 
15 - 30 
3 - 7 
cholestatic hepatitis 
enterocolitis 
pulmonary infiltrates 
bone marrow aplasia 
37 
12 
9 
bronchiolitis obliterans 
myasthenia gravis 
Goodpastures syndrome 
bone marrow aplasia 
Table II. Factors that increase the risk for the development of toxic 
reactions on gold salts and d-pemcillamine. 
gold salts d-penicil lamine 
high dosage(26) 
water soluble preparations(27,28) 
IgA deficiency(29) 
presence of IgE antibodies 
to gold(30) 
HLA B8-DR3(21) 
DR2(20) 
IgM rheumatoid factor negativity 
(proteinuria)(31) 
rheumatoid arthritis (32) 
short term intervals between 
dose increments(4) 
age beyond 60 years(33) 
impaired sulphoxidation(34) 
HLA DR3(21) 
DR4(35) 
History of gold salt induced 
toxicity (36) 
Genetical factors and rheunatoid arthritis 
Studies in the pre-HLA era have indicated that genetic factors are important 
in the development of rheumatoid arthritis. These studies include multiple 
case families and twin studies (9). HLA studies have indicated an association 
between rheumatoid arthritis and the antigen Dw4 and DR4, at least in clini-
cal patient populations (10). This association, however, was not found in a 
population survey (11). In addition to this association, several studies have 
mentioned an association between certain HLA antigens and the presence of 
certain extra-articular manifestations, like Sjogren's syndrome, Felty's syn-
drome and vasculitis (12,13,14). Family studies using HLA typing have so far 
not consistently shown segregation with one particular haplotype or antigen 
(15). Haplotype sharing did not reveal deviation from the expected distribu-
tion (16,17,18). At this moment no consensus exist whether HLA antigens are 
associated with seropositivity/seronegativity or a worse prognosis (10). 
Genetics of toxicity of antirheuaatic drugs 
At the start of the present study only few data were available on the effect 
of genetic factors on the development of toxicity of antirheumatic drugs. The 
first report was an asociation between levamisole-induced granulocytopenia 
and the HLA antigen B27 (19). As far as gold salts and d-penicillamine are 
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concerned, the first report was that of Panayi et al (20), who showed an as-
sociation between toxic reactions on these drugs and the HLA phenotypes DR2 
and DR3. In 1980 Wooley et al demonstrated an impressive association between 
aurothiomalate-jnduced proteinuria and HLA B8 DR3 (21). There was no signifi-
cant association between DP-induced proteinuria and the latter antigens. A 
study by Latts et al suggested an increased susceptibility for gold-induced 
toxicities in patients positive for the HLA antigen B12 (22). Finally, in 
1981 Cobi in et al (23) showed a clearly increased frequency of HLA DR3 in pa-
tients with aurothiomalate- or AuTG-induced thrombocytopenia. 
Aim of the study 
The present thesis reports studies on genetical factors influencing the pa-
tients reaction to two second line drugs using HLA antigens as a genetic mar-
ker system. The two second line antirheumatic drugs studied are AuTG, the pa-
renteral gold preparation used in this country (the preparation in use in 
Anglo-Saxon countries is aurothiomalate), and DP. We looked for genetic in-
fluence not only on the development of toxicity, but also on type of clinical 
response to the drug, both in groups of unrelated RA patients and in families 
with multiple cases of RA. 
By means of a case control study we investigated the association between HLA 
phenotypes and the development of proteinuria after AuTG or DPtreatment. Not 
only the development of proteinuria perse, but also its degree and time of 
onset were taken as variables (chapter 2). 
Since this study indicated differences in HLA-phenotype associations between 
AuTG- and DP-induced proteinuria, we investigated whether previous AuTG-in-
duced proteinuria is a risk factor for developing proteinruia during subse-
quent DP treatment as stated by some authors (37,38) (chapter 3). 
The most severe toxicities of both AuTG and DP are hematotoxic side effects. 
In chapter 4 we report data on HLA associations in AuTG- and DP-induced 
thrombocytopenias and leukopenias obtained in a case control study. 
Only scanty information exists on whether there is a genetic predisposition 
to a certain type of clinical response (excellent-, moderate- or non-respon-
se) to second line antirheumatic drugs. Chapter 5 reports data on HLA pheno-
type frequencies in groups with different types of response to AuTG treat-
ment, obtained in a large cohort study. 
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In the final part of this thesis we studied the reaction to either AuTG or DP 
in first degree relatives with RA treated with the same second line drug. The 
larger part of these patients were obtained from a large study project. Our 
studies were initiated by the observation of a remarkably similar reaction to 
AuTG therapy, both in terms of toxicity and clinical response, in two pairs 
of sibs, who proved to be HtA identical (chapter 6). Subsequently we collect-
ed 13 pairs of first degree relatives with identically treated RA and studied 
concordances in terms of toxicity and clinical response to drug treatment. In 
addition we studied the influence of HLA-haplotype sharing and sex on concor-
dancy (chapter 7). Details of the multiple case families mentioned above are 
given in the Addendum. 
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CHAPTER 2 
HLA-DR ANTIGENS AND PROTEINURIA INDUCED BY AUROTHIOGLUCOSE AND D-PENICILLA-
MINE IN PATIENTS WITH RHEUMATOID ARTHRITIS 
F Speerstra, Ρ Reekers, LBA van de Putte, JP Vandenbroucke, JJ Rasker, DJRAM 
de Roo ij 
Published in: 
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HLA-DR Antigens and Proteinuria Induced by 
Aurothioglucose and D-Penicillamine 
in Patients with Rheumatoid Arthritis 
H- Г/1 SPI I RSTR \ P M I R U K I R S LI \ IM S В \ чаи ik PI TI l J \ \ Ρ \ \ M ) I NHROl t k l 
JOHANN! S J R \ S k I R anil DIRK J R \ M ik ROOIJ 
•thsirUii B\ means of a lasi'-iontrol stud\ ne ini i s t icat id the association betwern IILA 
phenol\pes and the de%elopiiienl of proteinuria alter aunitliiogluiose or U-penicillainine treal-
ineiil in patients »ni l rheumatoid arthritis (RA) HI \ - l ) R l n a s m a r k i d h increased in 44 treat­
ment cases compared n i th 66 R\ lonlrols (46 »ersus 18 , ρ - 0 002) III λ 1)R1 posilite 
patients were at цгеаііг risk during Inatment nith D-peniiillamine (RR 10 1. ρ — 0 001) than 
gold treated lases (RR I V, ρ 0 16S) 1 he assoiiations b i t m e n HI A-DR1 and nephrotic s\n-
drome (RR _ 6 1, ρ - 0 004) and carl\ onsil proteinuria (RR - S 4, ρ <· 0 001) nere stroiiRer 
compared nith unconipliiatid proteinuria (RR ~ 1 Ι , ρ - 0 017) and late-onset proteinuria (RR 
- I 6. ρ 0 4^9), respiitiiel> It appiars lliat цепеііс factors in R \ influence the deii lopment, 
lilt dtijree and the linn of onset of dm); indutid proti inuna (У Rhuimulol 10 948-9S1. 1981) 
A( ι lililí \//íi ' lani'ì 
RUI L MAIOID ARTIIRIIIS III \ AN I ΙΟί Nb PROTHNLRIA 
Al ROIHIOC.U'COSL IMMLNOC.LNl TICS D PFNICILl AMINh 
Pat ients vmh severe r h e u m a t o i d arlhril is (RA) 
irealcd wiih a n n r h e u m a l i c drugs s u d i as aurolhio-
glucose ( О Т О ) and D - p e n i u l l a m i n e (DP) i s o l l e n 
complicated by loxic reactions s o m e t i m e s nccessi-
taling discontinuation of ihe drug M e c h a n i s m s 
underly ing the d e v e l o p m e n t of loxic reactions are 
obscure, and may nol necessarily be the same for 
d i l l e rent loxicities A compar i son ol patients with 
Wilson 's disease and RA receiving DP showed a 
higher frequency ol loxic react ions in patients with 
ftoni tin l)i/)(iininiit\ of Rhiiitiiutoloi,\ Liiiu.i\it\ ПІ)\/ІІШІ 
St RtnlbiHul aiiii St Vaailinsklmuk \ι/ιιια,αι Ηυψιηι! 
/и kinzo/1, 1 nu liuti Ни I ahiiiuinn ut 1 nìnsplciiuanon 
Simile Hhnitl Ίiiinstimon SiiMii innimì\ nf \//лмсі" 
and/IH Dnisiini "/1 /nihniiDlim I iusmit\ L nnmin Rumi 
ctam Uh \iituilantls 
Thi vmh was siififinnid b\ a Grani /ioni ilu RuMnittfinuh 
Tlu Начт anil Oi^anon Ini Os\ 7ht \illiiilanih 
f Spi mira UI) Dipainmnt ol НІнитапіІію Ρ 
Riikirs Rh l) Diuiioi ol Labinaion haififilanitiiion 
Simlinx L В 4 iati ih Rimi Pioltwoi Diftaiinutii ol 
RhttiniaioloKi i nniiun ol \i/nm,iη J f' \ aiiikiihionikt 
UP Dtpaiinmii of l iiiiUnitoloi!\ hiasnius іііпіті\ Rol 
iirilam J J Raskir U I) Dqiaitimni ol Rliaiinuiohw 
7/i ktnzoifi Hos/itial l militili anti I) J R \ \f th Roon 
U l) Dtpainmni ol Rli4iniaioloii\ Si Uaaiitnskliimk 
\ if nu цеп 
AMnss nqiitsis Im iipiini', io Di f Spai stia Dipaiimini 
ol Rlniinniíoloi\ Lni\tmi\ tlospital Si Riitlbinid inni 
Grooiiplan /IIIÍI V ήιίίΟ I/H \iiini utn Ί/ιι \iilittltiiith 
Siibnniktl Dtttmbti 1^ 1442 ii\isioii aittpitt/ Ipnl 7 
R X ' , suggesting thai pat ients with RA are m o r e 
prone lo drug loxicity 
Resul t s of several recent s tudies have suggested 
a genetic basis lor al least s o m e toxic reacl ions m 
a n t i r h e u m a t i c drugs in pat ients wiih RA Veys, et 
« Г ' reported that the possession ol the HLA-B27 
ant igen correlates with an increased risk of gra­
nulocytopenia in pat ients with RA taking levami-
solc In addit ion, Panayi et al* showed that RA 
pat ients positive lor H L A - D R 3 or D R 2 had an in­
creased risk ol toxic m a n i l e s l a u o n s during treat­
m e n t with sodium a u r o t h i o m a l a t e ( G S T M ) or D P 
Recently Wooley, et а Г reported an increased 
Irequency of II LA -DR 4 m pat ients with proteinuria 
taking G S T M or D P They calculated a relative risk 
of developing proteinuria dur ing G S T M therapy of 
32 in these D R 3 positive pat ients Since a relative 
risk ol this order of magni tude may have practical 
c o n s e q u e n c e s , we studied a large series of RA 
pat ients with gold- or D P - m d u c e d proteinuria seen 
at our hospitals In this case-control study we 
l o o k e d for poss ib le a s s o c i a t i o n s b e t w e e n the 
d e v e l o p m e n t of proteinuria dur ing G T G or D P 
therapy and HLA ant igens 
M A I L K I A I S AND M H HODS 
Pamiit\ I orty tour patients with definite or classical RA 
according to the ARA с т е п а 6 developed proteinuria 
cither on O T C J or on DP or on both were entered into 
siuily Data were collet led from laboratory chctk lists and 
clinical notes on patients treated during the past 10 years 
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at the University Hospital and St Maartenskliniek 
Nijmegen (28 patients) and at the Ziekenzorg Hospital, 
Enschede (16 patients) both cities situated in the eastern 
part of the Netherlands A 1st control group consisted of 
66 patients with definite or classical RA »ho had been 
treated for at least 12 months with either drug without 
signs of proiemuria on routine testing A 2nd control 
group consisted of 277 healthy blood donor volunteers 
randomly selected and typed over the same period as the 
RA patients Characteristics of both patient groups are 
shown in Table 1 Fxtraarticular manifestations such as 
nodules, Sjogren's syndrome, vasculitis. pol\serositis and 
Felly's syndrome occurred in 58 patients and were more 
frequent in the proteinuric group A positive family history 
for RA obtained b\ direct questioning was equally fre­
quent in patients and RA controls 
Dim; regimen ami louitn GTCi (50 mg IM) was given 
weekly to a cumulative dose of 1000 mg, the dosage was 
then reduced lo a maintenance dose of 50 mg/4 weeks 
Ш' was prescribed in an initial dose of 250 mg/day with 
increments up to 1000 mg in some depending on the clini­
cal response Monitoring for side effects (physical 
examination, leukocyte count and differential, platelet 
count and routine testing for proteinuria) was initially 
done weekly and later on during maintenance therapy at 
least oncc/6 weeks Proteinuria found on routine testing 
was quantnaied in g/24 h (28 patients) or g/l ( 16 patients) 
The criterion for inclusion in the patient group was pro­
teinuria of more than 1 g/24 h or 1 g/l The proteinuria 
was considered to be drug induced only if it reversed after 
discontinuation of therapy I or inclusion in the R Λ control 
group, routine tests had to show no proteinuria for at least 
one year Of the 44 proteinuric patients studied, 22 were 
OTG and the other 22 DP induced Twelve of the pro­
teinuric patients fulfilled the criteria lor nephrotic syn­
drome Rectal biopsies ol 5 of these cases showed no 
deposition of amyloid Glomerular function as indicated 
by serum creatinine was unaffected in all cases but pro 
tcmuna persisted for months after discontinuation of 
therapy and in some cases proteinuria was still traceable 
after one year 
HLA hpmg Typing for ill A-Α, B, and С antigens was 
done according to Mutai ei ol' by slandardi/ed NIH 
microly mphocv loloxicuy techniques, using 118 sera for all 
established IILA-A В and С antigens, including BW4 
1 able 1 Clinical characteristics of the RA patients 
(n = 44) and RA controls (η = 66) 
Age (median) 
Male female ratio 
IgM rheumatoid factor 
positive) %) 
A4Aposilive(%) 
Extraarticular 
manifestations ( % ) 
Family history positive ( % ) 
Cases 
58 
1 3 
95 
52 
68 
29 
RA Controls 
60 
1 3 
95 
40 
41 
28 
and BW6 and low frequency W specificities (class 1 anti­
gens) HLA-DR typing »as done on enriched В 
lymphocyte suspensions obtained after resetting »uh 
ALT treated sheep red blood cells8 The 58 test sera for 
typing antigens DR1 through DRW 10 (class II antigens) 
were partly of local origin and partly obtained by national 
and international exchange all sera being standardized 
against the 8th International Histocompatibility Workshop 
sera
4
 and also during the Dutch В cell Typing Work Shop 
(1981) 
bianstitalanahvs The increase in risk associated with cer­
tain HLA types was expressed asa relative risk (RR) esti­
mated from the case control data by means of the 
exposure odds ratio10 To evalúale whether the RR esti 
mate differed significantly from unity (its expected value 
under the null hypothesis of no association), we calculated 
the Manlel-Haenszel Chi-square statistic", and obtained 
2-sidcd ρ values Finally, we computed 950o confidence 
limns of the RR estimate12 to give an impression of the 
statistical uncertainly involved In ihe tables we use the 
following notation to distinguish the relative risk estimates 
associated with a certain HI A antigen (indicated in 
brackets) among the cases and the 2 control groups RRCR 
is the relative risk when cases are compared to RA con­
trols, RRcn is the relative risk when cases are compared to 
healthy controls, and RRRH IS the relative risk when RA 
controls arc compared to healthy controls RRCR gives 
contrasts in HLA antigen that are associated with the 
development of proteinuria to the drugs studied RRcn 
compares RA patients who developed proteinuria »uh the 
healthy population, while RRRH compares the other RA 
patients (those not developing proteinuria to the drugs 
studied) with the healthy population 
RESULTS 
Table 2a compares HLA-DR gene products in pa­
tients, RA controls and healthy controls The dif­
ferent calculable RR estimates of interest are tabu­
lated in Table 2b The frequency of antigen DR4 
was significantly increased in both patients and RA 
controls as compared with healthy controls, while at 
Ihe same lime Ihe prevalence of DR4 did not sig­
nificantly differ between patients and RA controls 
Antigen DR3 was significantly increased in patients 
as compared with RA controls, while at the same 
time the prevalence of DR3 did not differ signifi­
cantly between RA controls and healthy controls 
Table 3 shows the association between antigen 
DR3 and proteinuria for all patients and for GTG 
and DP-mduced proteinuria, respectively Λ higher 
RR regarding this antigen was observed for DP 
than for GTG When the presence of HLA-DR3 
was compared between patients with nephrotic syn­
drome and those with uncomplicated proteinuria, 
the RR was higher in the former than in the latter 
group (Table 4) In addition, DR3 positive cases 
developed proteinuria earlier than did DR3 nega­
tive cases (Table 5) 
2k 
Table 2a Distribution of HLA -DR antigens in RA patients, RA controls and healthy controls 
HI A-DR 
Antigen 
RA I'aüenisln = 44) 
No % 
RA Controls (η = 66) 
No % 
Healthy Controls (η : 
No 
'277) 
DR 1 
8 
9 
10 
Π 
7 
20 
20 
6 
9 
5 
2 
1 
0 
26 
16 
46 
46 
14 
21 
12 
5 
2 
0 
32 
18 
18 
55 
23 
18 
14 
4 
4 
3 
70 
8 
2 
25 3 
32 1 
23 I 
196 
23 5 
26 4 
20 0 
57 
30 
07 
Table 2b. Estimates of the relative risks regarding antigens DR3 and DR4* 
RR R H (DR3+) 
RRC H<DR3+) 
RR t R (DR3+) 
R R R H ( D R 4 + ) 
RR C H (DR4+) 
RRC 1 1(DR4+) 
Point 
Eslimalf 
07 
28 
38 
50 
34 
07 
95% Confidence 
Interval 
04 
1 5 
1 6 
29 
1 8 
0 3 
1 5 
52 
87 
85 
65 
1 5 
p-Value 
(2-sided) 
0 388 
0 002 
0 002 
<0 00l 
< 0 001 
0 352 
Notation, see Materials and Methods 
Table 3 Association between proteinuria induced bv GTG or DP and antigen HLA-DR3 Results obtained 
from 44 RA patients and 66 RA controls 
Relative Risk (DR 3) 
Drug DR3 
RA Patients 
(n - 44) 
No 
20 
24 
7 
15 
13 
9 
RA Controls 
(n = 66) 
No 
12 
54 
9 
33 
3 
21 
Point 
Estimate 
37 
1 7 
10 1 
95% 
Confidence 
Interval 
1 6 - 8 7 
0 5 - 5 5 
2 5 - 40 3 
ρ Value 
ρ - 0 002 
ρ = 0 3 6 5 
ρ = 0 0 0 1 
GTG or 
DP 
GTG 
DP 
+ · 
+ 
+ present 
— absent 
25 
Table 4 Frequenz of аппцсп DR f m KA patienis 
viiih and viithoul nephrotic wndiome (\'S) 
Anügen DR 3 
Present 
Absent 
RRCR 
95% Cl 
ρ Value 
RA Patients 
NS Present" 
η = 12 
7 
5 
63 
18 213 
0 004 
NS Absent 
η = 32 
13 
19 
3 I 
1 2 7 8 
0017 
RA Controls 
η - 6 6 
12 
54 
' This category includes 4 NS induced by GTG and 8 \S in 
duced by DP 
brequcncics of ULA-A, B, and С antigens did 
not differ significantly between patients RA con­
trols and healthy controls except for antigen B8 in 
the patients, which reflects the linkage disequili­
brium with antigen DR3 Of those patients and 
healthy controls that were HLA-DR3 positive, 17 
out of 20 patients (85%), 8 out of 12 RA controls 
(66%), and 43 out of 64 healthy controls (67%) also 
were B8 positive On the other hand, 17 out of 21 
patients (82%), 8 out of 17 RA controls (50%) and 
45 out of 64 healthy controls (70%) that were HLA 
B8 positive also possessed antigen DR3 Although 
the combined occurrence of antigens B8-DR3 was 
found more frequently in the patient group, this 
frequency was not stalistically different from that 
observed in RA controls and healthy controls Anti 
gen DR2 was decreased in both patient groups as 
compared with healthy controls, at a statistically 
significant level (p = 0 02 with correction for the 
number of DR antigens tested for) 
DISCUSSION 
Our case-control study shows an increased fre­
quency of HLA-DR3 in patients developing pro 
Table 5 Relation between earh onset proteniiina 
(•ЛІІІІІП one \ear after mstnutum of llierap\) anil anti­
gen DR ? 
DR3 Present 
Absent 
RR 
95% CI 
ρ value 
RA Pabents 
Early Onset 
16 
13 
54 
22 140 
<0 001 
Late Onset 
4 
Π 
1 6 
0 4 6 0 
0 459 
RA 
Controls 
12 
54 
teinuria on GTG and DP as compared with the non-
proteinunc controls The strongest association be 
twecn the presence of HLA-DR3 and proteinuria 
existed in the DP treated cases and in those who 
presented with nephrotic syndrome 
Wooley, et αΓ reported that the RR ol develop­
ing ol proteinuria on GST VI man Hl A-DR3 positive 
person would be as high as 32 We could not con­
firm this high RR estimate In our sludy the RR 
associated with GTG was 1 7, and it was not 
statistically significant at the 5% level By contrast, 
in our data the RR estimate with DP was 10 1 and 
was statistically highly significant This RR estimate 
is somewhat higher than the 4 5 reported by 
Wooley PI аГ and the 3 9 by Stem, it aln Our 
overall RR (both modes ol treatment) was 3 7, and 
statistically significant at the 5 о level Although our 
case senes was about twice as large as that reported 
by Wooley, et аГ which will in principle result in 
more stable estimates the fact remains that the 
separate tabulation of the effects of HLA-DR3 on 
each of the drug regimens results in small numbers 
in the cells of the 4-fold tables Most likely, it is the 
smallness of these numbers that is responsible for 
the widely divergent RR estimates To give an 
impression of the rather wide ranges of the esti­
mates that result from our data, we have reported 
in the tables the 95% conlidence intervals ol the 
estimates as well Another possible factor con­
tributing to the discrepant findings may be the use 
of dilferent gold preparations — GSTM versus 
GTG in our series Both preparations possess the 
aurosuphur group attached to cither malate or 
glucose The difieren! physical properties are deter­
mined by the hydrophy lie groups both preparations 
are soluble in water, but only GTG can be sus­
pended in oil Water soluble preparations are more 
rapidly absorbed after injection, resulting in 
immediate higher blood levels and consequently a 
larger urinary loss of gold shortly alter administra­
tion These peak levels are avoided by using pre­
parations suspended in oil such as GTG It is con­
ceivable that these mechanisms play a role in the 
observed significantly increased incidence ol toxic 
reactions including proteinuria during GSTM 
administration as compared with GTG 1 4 
Possible mechanisms underlying the association 
between DR3 and gold and DP induced proteinuria 
are still obscure Renal biopsy studies from gold or 
DP induced proteinuria have indicated that the 
lesion is probably a membranous type immune 
complex (1С) glomerulonephritis 1 , " Recent 
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studies have shown an increased frequency of 
HLA-DR3 in several diseases, e g , type I diabe­
tes mellitus, Sjogren's syndrome, membranous 
glomerulonephritis. Graves ' disease, systemic 
lupus erythematosus (SLE), chronic active hepa­
titis, celiac disease, myaslhenia gravis and derma­
titis herpetiformis' In addition, RA patients posi­
tive for the HLA-DR3 antigen show more extra­
articular manifestations'4 Since the above men­
tioned diseases are generally thought to be of 
autoimmune origin, the presence of HLA-DR3 
may predispose to autoimmunity and/or 1С disease 
One possible explanation may be that gold salts and 
DP act as a hapten that leads io autoantibody for­
mation and possibly lo 1С disease Another intrigu­
ing possibility is suggested by a recent study on 
patients with dermatitis herpetiformis18 In this 
study it was shown that 50% of the patients, all posi­
tive for antigen B8 or DR3 or both, had a delayed 
Fc receptor mediated clearance of IgG-sensiti/ed 
autologous erythrocytes as compared with normal 
controls A similar defect was also found in half of 
the healthy controls positive for HLA-B8/DR3 In 
this respect it may be relevant that 85% of our DR3 
positive patients also possessed the HLA-B8 anti­
gen, whereas only 66% of the RA controls and 67% 
of the healthy controls positive for DR3 were also 
HLA-B8 positive If Fc receptor-mediated 
clearance is indeed delayed in patients having the 
HLA-B8/DR3 antigens, then accumulation of 
GTG in the reticuloendothelial system, which has 
been demonstrated1'1, could accentuate this defect, 
leading to more circulating 1С and eventually to 1С 
disease 
Other, as yet unexplored factors, may also be 
important This is well illustrated by another exam­
ple of drug induced disease, ι e , hydralazine 
induced SLE Drug metabolism seems to be a cru­
cial factor in its pathogenesis, since the disease 
occurs more frequently in slow than in rapid 
acetylators™ In addition, this is a good example of a 
drug induced disease with more than one contribut­
ing factor A recent study21 demonstrated that a 
combination of female sex, DR4 positivity and slow 
acetylatorship increases the risk of hydralazine 
induced SLE up to 100% That different mechan­
isms may be operative in the various side effects of 
one drug is also indicated by the fact that Wooley, el 
al5 were unable to demonstrate associations be­
tween other toxic effects on GTG and DP and 
HLA-D antigens Preliminary data from our group 
confirm this observation, at least so far as gold 
induced rashes are concerned In contrast we 
observed 2 cases presenting with severe gold 
induced thrombocytopenia and 2 additional cases 
with severe and recurrent granulopenia on both 
gold and DP All 4 patients were positive for anti­
gen DR3 Coblm, el al22 found a strong association 
between thrombocytopenia induced by GTG and 
antigen DR3 Recently, Bardin, er al" reported on 
the positive association of toxicity secondary lo a 
different gold salt, aurolhiopropanololsulphate, and 
antigen DR3 A minority of these patients pre­
sented with proteinuria and hematologic side 
eftects 
Our results seem to suggest that patients with 
HLA-DR3 are at higher risk for developing pro­
teinuria during DP therapy We feel that these 
observations need confirmation Prospective stu­
dies should be done to determine the actual risk 
in this phenotypic subset Meanwhile, in our opi­
nion there is no firm reason to perform tissue typ­
ing before DP is started This is because the 
associations found are definite but not very strong, 
the alternatives in drug treatment are limited, and 
drug induced proteinuria is reversible and very 
rarely leads to renal function impairment 
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The relationbhip between aurothioglucose- and n-penicillamme-mduced proteinuria. (Sub­
mitted September 15, 1981 and in revised form December 7. 1983 ) Scan J Rheumatology 
13 363-368, 1984. 
We studied patients with rheumatoid arthritis who have been treated with aurothioglucose 
(Au) and subsequently with D-penicillamme (DP), and who developed drug-induced pro-
teinuna. over a 10-year penod Twelve patients developed Au-induced and 19 DP-induced 
proteinuria Of the 12 patients with Au-induced proteinuria, only 2{\T9e) developed DP-
induced proteinuria, indicating a slightly increased risk as compared wilh the overall 
incidence (9.3 </c) of this reaction in 168 DP-lrealed patients In addition, only a minonly (2 
out of 19, 10 (¡r/c) of patients with DP-induced proteinuria had previous Au-induced 
protemuna These data may indicate that different mechanisms are operative m Au and 
DP-induced proteinuria, as is also suggested by the finding that HLA-DR3 was present 
more frequently in the latter (50%) than in the former (21 c/c) A history of previous Au-
induccd protemuna is insufTicient reason to deny these patients the benefits of subsequent 
treatment with DP. 
F Speerstra, University Hospital St. Radboud, Department of Rheumatology. Geert 
Grooteplein Zuid H, 6500 HB Nijmegen, The Netherlands 
In recent years D-penicillamine has become recognized as a major antirheumatic agent (15, 
25). The drug is frequently used after gold therapy has caused toxic reactions or proved 
ineffective. The frequency of side effects of D-penicillamine is comparable to that of 
intramuscular gold and the toxic reactions to both drugs show a considerable overlap (4, 
6). From a practical point of view it would be important to know whether patients whose 
severe toxic reactions to gold necessitate discontinuation of the drug, ran a greater risk of 
developing similar toxic reactions to D-penicillamine. Data on drug-induced proteinuria 
have so fare been contradictory. Several studies suggest that patients with D-pemcilla-
mme-induced proteinuria frequently have a history of gold-induced proteinuria (7, 3, 6, 
19), whereas others have been unable to find such an association (13, 27). 
In a recent study we looked for associations between HLA phenotypes and aurothioglu-
cose- or D-pcnicillamine-mduced proteinuria in patients with rheumatoid arthritis develop-
ing this type of side effect (20). We found HLA-DR3 to be significantly increased in 
patients with D-penicillamine-induced proteinuria, but not in those with aurothioglucose-
induced proteinuria, suggesting a difference in the pathogenetic mechanism involved. We 
then studied the relationship between aurothioglucose- and D-penicillamine-induced pro-
teinuria by selecting from the above series those proteinuric patients who had been treated 
with both drugs, in all cases D-penicillaminc treatment following treatment with aurothiog-
lucose. 
This should inform us about the number and clinical characteristics of patients who 
developed proteinuria on both drugs and therefore give us an estimate of the recurrence 
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rate of proteinuna in D-pemcillamine-treatcd patients who had previously developed this 
type of side effect on aurothioglucose Our results indicate that patients with aurothioglu 
cose-mduced nephropathy run only a slightly increased nsk of developing D-penicillamine-
induced proteinuna 
Selection of pariente 
Patients for the present study were selected from a larger series of 44 patients with classical or definite 
rheumatoid arthritis (RA) (14) and drug induced proteinuna studied for other purposes and reported 
on elsewhere (20) This senes included all patients with RA and proteinuria (see below) on aurothiog­
lucose (Au) D-penicillamine (DP) or both seen at two centres for rheumatic diseases in the eastern 
part of The Netherlands (Nijmegen and Fnschede) between 1972 and 1982 
For the present study we selected from this senes only those (29 out of 44) who had been treated 
with both drugs, in all instances DP after Au This group of patients would allows us to study the 
frequency of proteinuna on DP after Au-induced proteinuna and would also inform us about the 
frequency of earlier Au induced proteinuna in patients who developed DP induced proteinuria The 
cntenon for inclusion was proteinuna of more than one gramme per 24 hours or one gramme per litre 
The proteinuna was considered to be drug induced if И reversed after discontinuing the therapy 
Patients with pre-exislent renal disease, chronic unnary tract infections or longstanding diabetes 
mellitus were not included 
If it is stated that either of the two drugs had not induced proteinuna this means that this particular 
drug had been used for at least one year without development of proteinuna or that the drug had tobe 
discontinued in view of other toxic reactions or ineffectiveness (usually after 6 months of use) Since 
we had to compare the frequency of proteinuria on DP in patients with previous Au induced 
proteinuna vis à vis that in an unselecled group of DP-treated patients we calculated the latter from 
the number of DP-mduced prolemunas (л-16) as a percentage of all patients who had received the 
drug between 1972 and 1982 (л=172) at the centre for rheumatic diseases in Nijmegen 
Dose regimen and drug monitoring 
Aurothioglucose (50 mg ι m ) was given once a week up to a cumulative dose of 1000 mg. thereafter 
the interval was prolonged to 2-4 weeks D-penicillamine was prescnbed m an initial daily dosage of 
250 mg Increments were made according to the go-slow-go-low regimen (8) up to 7S0-1000 mg in 
some Unnalysis for proteinuna was done using the dip-stick method initially weekly and subse­
quently once every 4-6 weeks If proteinuna was detected the amount was quantitaled in grammes 
per 24 hours or per litre 
HLA typing 
Typing for HLA ABC antigens was done according to Mittal et al (12) by standardized NIH 
microlymphocylotoxicity techniques, using 118 sera for all established HLA ABC specificities 
including Bw4, Bw6 and low frequency W specificities HLA DR typing was done on ennched B-
lymphocyte suspensions obtained after rosetting AF,T-trcated sheep red blood cells (9) The 58 test 
sera for typing antigens DR I through DRwIO were partly of local origin and partly obtained by 
national and international exchange, all sera being standardized against the 8th International Histo­
compatibility Workshop sera (26) and also dunng the Dutch B-cell typing Workshop m 1981 
Statistical methods 
The relative nsk of developing proteinuna on o-pemcillamine in a patient with a history of Au induced 
proteinuna was computed together with 95% confidence interval by the calculator programs of 
Rothman & Boice (16) The 95% confidence interval gives an estimate of the statistical uncertainty 
which is involved in the relative nsk estimation, if unity falls outside the 95 % confidence interval the 
relative nsk is statistically significant at the 5 % level 
RESULTS 
Recurrence of proteinuna 
Protemunc patients could be divided into three groups those with proteinuna on Au, but 
not on DP (Au+ DP-), those with proteinuria on DP but not on Au (Au- DP+), and those 
with proteinuna on both drugs (Au-l- DP+) (see Table I) Thus, 2 of the total of 12 Au-
induced proteinurias (17%) recurred on DP, whereas 10 (83%) did not Of the latter 10 
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patients, 7 had to discontinue DP after 14 to 84 months 2 because of loss of benefit and 5 
because of intestinal complaints I hree patients are still using DP Table I also shows that 
2 of the total of 19 patients with DP-mduced proteinuria (99c) previously had Au-mduced 
proteinuna One of these patients developed clinical nephrotic syndrome during both 
modes of treatment In the remaining 17 patients Au was stopped after 6 to 120 months for 
the following reasons rashes (8 patients), loss of initial benefit (7 patients) and prolonged 
remission (2 patients) Nephrotic syndromes were more frequently found in the DP-
induced proteinurias (7 out of 19) than in the Au-induced proteinurias (3 out of 12) The 
same applies to the frequency of HLA-DR3, but HLA-DR4, seropositivity and extra­
articular manifestations were equally distributed among the groups (Table I) 
Table H shows data on our proteinuric patients and controls and data from the literature 
Our results indicate that the frequency of DP-induced proteinuna after Au-induced pro­
teinuna is 17%, as compared with an overall incidence of 9 3 % This gives a relative risk 
of 1 7 with 95 % confidence intervals between 0 5 and 7 1 
DISCUSSION 
We determined the nsk of proteinuna as a toxic reaction to D-penicillamine in RA patients 
who had previously suffered from aurothioglucose-mduced proteinuria The incidence of 
D-penicillamine-induced proteinuna in these patients was 17% (2/12) and turned out to be 
only slightly higher than the overall incidence of proteinuria during D-penicillamine treat­
ment (9 3%) Although the higher frequency (a relative nsk of 1 7, ι e almost twice as 
high) may suggest that D-penicillamme-induced proteinuna is more likely to occur in the 
patient with a history of Au-induced proteinuna, this estimate is not significant at the 5% 
level and cames a wide confidence interval (0 5 to 7 1) due to the small number of 
observations Evidently, as our findings demonstrate, the majonty of patients with a 
history of proteinuna on gold are able to use D-penicillamine later on, indicating that the 
predictive value and consequently the clinical relevance of this anamnestic information is 
limited In this context it should be realized that proteinuna caused by either of these 
drugs nearly always takes a benign and self-limiting course From these data it seems 
Table I Clinical data and HLA DR antigen frequencies of 29 proteinuric patients 
First 
signs of Ne- HLA DR antigen frequencies 
prote- phrotic (no of patients) 
No of inuna syn- Disease 
Subset" patients (months) rome manifestations DR1 DR2 DR3 DR4 DR5-I0 
A U ' D P 10 2-12 2 ANA (4) IgMRF (10) 1 2 3 6 7 
nodules (8) Sjogren (1) 
vasculitis (1) 
Au*DP* 2 2-3 1* ANA (2) IgMRF (2) 1 2 
nodules ( I ) Sjogren ( I ) 
vasculitis (2) 
Au DP + 17 2-18 6 ANA (9) IgMRF (16) 3 2 8 6 II 
nodules (12) Sjogren (3) 
vasculitis (I) 
" Au+DP", patients with proteinuna on aurothioglucose but not on »penicillamine, Au*DP*, patients with 
proteinuna on both aurothioglucose and D-penicillamine Au D P ' , patients with proteinuna on D-pemcillamme but 
not on aurothioglucose — * See text 
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justifiable to treat RA patients with D-penicillamine when gold has to be discontinued 
because ol proteinuria 
Data published on this subject have so far been controversial (Table II) (4 4, 6 7 10 Π 
19,21,22,25 27) Observations reported by Billmgsley & Stevens Π) Halla et al (6) and 
Smith et al (19) suggest an increased risk of D-pcnicillamme induced proteinuria in 
patients with previous gold-induced proteinuria but Webley & Coomes (27) found no such 
association However, it should be realized that the studies summarized in I able II are not 
readily comparable as there are major difTerences between them Important in this respect 
are the variations in the percentages of patients previously treated with gold and in the 
criterion for drug-induced proteinuria Regarding the latter it is interesting that the studies 
of Billmgsley (3) and Halla (6) suggesting an increased risk of recurrence, both used a 
lower inclusion criterion for proteinuria (0 4 g) than Webley s study (27) and our own 
study (>1 g), we were both unable to demonstrate a significantly increased risk The 
question arises whether inclusion of minor proteinuria increases the risk of including non-
drug-related proteinuria This is not inconceivable since mild glomerular pathology unre­
lated to gold or D-pemcillamine has been demonstraled in patients with rheumatoid 
arthntis (28) Moreover, minor but variable proteinuria often follows significant gold-
induced proteinuria sometimes for a considerable time (18), and may be mistaken for D-
pcnicillamine-mduced proteinuria 
The fact that the overlap between gold and n-penicillamine-induced proteinuria is onlv 
small, suggests that different mechanisms are operative in proteinuria induction by the two 
Table II Incidence of proteinuria induced h\ t) penicillamine with reference to prenions цоісі induced 
proteinuria 
Group 
0 of 
atienls 
Incidence of 
proteinuria 
induced bv 
D penicillamine 
ΛΜ%> 
Previous 
irealment 
with gold 
Г/г) 
Recurrence 
of 
prolemurid 
N (r/r) 
Definition of 
drug induced 
piolemuna 
Present series0 
All palients with gold-
induced protemuna with 
D-penicillamine later on 
All patients treated with 
D-penicillamine 172 
2(17) 
16 (9 3) 
> l g 
Previous series 
1974 multicentre trial group S4 
1977Tsang el al 44 
1979 Webley el al 144 
1979 Stein et al 110 
1980 Slem et al 219 
1980 Hylland et al 56 
1980Doddeta l |S5 
1981 Billmgsley et al 25 
1982Keanelal 114 
1982 Smith et al 405 
1982 Halla et al 90 
1982 Steven et al 44 
9(17) 
2 ( 5 | 
Il (10) 
Noi itated 
19(7) 
3(5) 
Not staled 
6(24) 
11(11) 
20(5) 
14(16) 
5(11) 
54 
100 
65 
69 
59 
84 
19 
84 
47 
18 
100 
Not staled 
1 (50) 
None (0) 
4 ( 4 
Not stated 
2(70) 
1(7) 
5(83) 
1(21) 
4(40) 
8(57) 
Not stated 
+ dipstick 
> 2 g 
>i в 
Nol stated 
>0 5 g 
Nol staled 
Nol stated 
> 0 4 g 
+ dipstick 
Not slated 
>0 4 g 
> 0 4 g 
" Including all registrations between 1972 and 1982 
ih 
drugs Two of our observations support this birstly. in previous studies we (20) and others 
(23) have shown that D-pemcillamine-mduced (but not gold-induced) protcinuna is strong­
ly associated with HLA-DR3 This observtion is at vanance with other studies (29, S), 
probably due to differences in patient selection and/or the use of a different gold salt, ι e 
aurothiomalate instead of aurothioglucose (11) Secondly, clinical nephrotic syndromes 
are more frequent in the D-pcnicillamine- than in the gold-induced proteinuna group This 
observation confirms those of others (1) It should be borne in mind that interpretations of 
such data may be biased to some extent by patient selection, since patients receiving D-
penicillamine frequently have a history of gold intolerance The HLA haplotype 
Al B8Cw7DR3 is found more frequently in patients with gold toxicity (2). suggesting that 
the proportion of these antigens may be higher in patients treated with D-pemcilUmine 
than in patients who receive the first course of gold 
On the other hand, we cannot exclude the possibility that the above-mentioned differ­
ences are merely an expression of differences in dose regimen ot the two drugs, since 
clinical experience suggests a dose dependency of gold- and D-pcnicillamme-induced 
proteinuna, in addition, the glomerular abnormality most commonly found is the same in 
both gold- and D-pemcillamine-induced proteinuna, ι e membranous type glomerulone-
phntis On the other hand observations made by Samuels et al (17) seem to suggest that 
this type of glomerular lesion may be aetiologically associated with rheumatoid arthritis, 
usually presenting with mild symptoms 
From a clinical point of view, it appears from these retrospective data that gold-induced 
proteinuna is insufficient reason to deprive a patient with rheumatoid arthritis of further 
treatment with D-penicillamine Moreover, our data do not warrant an increase in the 
frequency of regular check-ups for proteinuna dunng treatment in cases of previous gold-
induced proteinuna 
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HLA associations in aurothioglucose- and D-
penicillamine-induced haematotoxic reactions in 
rheumatoid arthritis 
l· S I M I R S I R \ . P Ri ι M RS', I В A VAN пь P u n t ' a n d J Ρ V \ N D I NBROI ΓΚΙ ' 
Dcp.Htmcnt ol Khcum.iUild^v .nul Ir.mspl.intation Serology, Uni\ersit\ Hospital St R.idboud. 
Nijmegen anti I)eptirtnicnt of f pitlcmiologv, I r.ismns Universitv. Rotterdam, I he Netherlands 
HI Λ phenolvpe frequencies were studied in 21 rheumatoid arlhnlis (RA) patients 
with haematotoxic reaUions lo aurothioglucose (Au I Ci) or D-penicillamine (DP), 
(is mateheil RA controls ami 277 healthy controls 
Antigens BS and OR^ were signifieantlv increased in the toxic RA patient group as 
compared to both RA controls and heallhv controls These contrasts were strongest 
in the palienls with AuIC-mduccd thromboevtopema or leucopenia all patients 
developing cither reailion m this drug were B8- and'or DRVposilivc (p <0 (Xll), 7 
(7S"i>) being positive for both antigens In the patient group with DP-mduced re­
actions these antigens were also increased hut these dillerences were not signifi­
cant In the latter group the prevalence of antigen DR4 was high. especialK m the 
patienl group with DP-mduced thmmbocylopcma .ill 12 patients with this type of 
reaction being DR4 positise 
Our dala suggest that haemalotnxic reactions to Au IG and DP develop primarily 
(or even exclusively) m genetically predisposed RA patients Furthermore, the 
HLA phenotype contributing to an increased risk seems not to be the same for the 
two anti-rheumatic drugs studied 
Knened for publication 10 September IV84, revised, accepted II hebruars I98Î 
Patients with severe rheumatoid arthritis 
(RA) are olten treated with disease modifying 
drugs like aurothioglucose (Au'lG) and D-
penicillammc (DP) However, treatment with 
these drugs is frequently complicated by side 
effects, including dermatitis, proteinuria and 
haematotoxic reactions, often necessitating 
discontinuation of the drug Recent studies 
have indicated an association between HI.A-
DR3 positivity and the risk of developing pro-
teinuria on aurothiomalatc (Gran et al 1983, 
Wooley et al 1980) and D-penicillamine 
(Speersira el al 1983). Since only a minority 
of the HLA-DR3-positive RA patients de-
velop proteinuria and since proteinuria is 
nearly always reversible and seldom a serious 
life-threatening condition, this association is 
at the moment ot little practical value On the 
other hand, haematotoxic reactions to AuTG 
and DP arc serious and sometimes life-thrcat-
enmg The available information on HLA as-
sociations with these reactions is scanty (Co-
v 
blin et al 1981) In the present study we re­
port on HLA associations with Au IG- and 
DP-induccd hacmatotoxic reactions and their 
possible practical implications 
Material and methods 
Selection of patients Records of all patients 
with classical or definite rheumatoid arthritis 
(RA) attending the Department of Rheuma 
tology between 1976 and 1984 were reviewed 
for thrombocvtopenia or leucopenu during 
treatment with aurothioglucose (AulG) or 
D penicillamine (DP) 
Twentv one ( aucasian patients (12 females 
9 males) were identified varying in age be­
tween 21 and 74 \ears (median ^4 years) at 
the time ot registration of the side effect 
Table 1 lists the time of onset after the start 
of treatment and the seventy ot the reaction 
Seventeen patients had one type ot reaction 
Patients 19 and 20 had a simultaneous fall of 
leucocytes and thrombocytes on Au I G Pa 
lient 18 had agranulocytosis on Au IG and 
subsequently leucopenia after switching to 
DP and patient 19 had leucopenia on AuTG 
and thrombocytopenia on DP In summary 
there were 2'S reactions 6 leucopenuis (4 on 
Au IG 2 on DP) 19 thrombocytopenias (7 on 
A u I G 12 on DP) and with refeience to ex­
posure theie were 11 Au I G-mduced and 14 
DP induced reactions 
Table I 
(Imitai (Uliiih ami III Λ phtimi\pe\ of 21 RA palimi·; nuli lumuioloxu nattions on Au Id' ami DI' 
Patient 
1 
2 
1 
4 
6 
7 
X 
9 
It) 
II 
12 
Π 
14 
Is 
Ift 
17 
IX 
19 
20 
21 
Ьх pos urc 
A u l C , 7 
1 
2(1 
9 
4 
DP In 
Ί 
5 
4 
ft 
•i 
4 
4 
1 
ft 
2(1 
1 
A u I G 2 
DP Я 
Л и Т Г . λ 
DP 4 
A u I G 2 
2 
months 
weeks 
months 
months 
weeks 
months 
weeks 
Read ion 
I P ' 
I P * 
I P 
I P 
I P 
I P 
I P 
7 
S 
80 
10 
S 
1 
74 
ni 
120 
H4 
«S 
4ft 
ft9 
SS 
X7 
KS 
7ft 
x l ( ) / l 
x l ( ) / l 
xio' i 
χ 1071 
X10/I 
7 x 1 0 1 
x l O I 
X10/I 
x 1071 
x l l l / l 
x l O / l 
Х І 0 / І 
x l ( l / l 
x H I / l 
x l O / l 
x l O / l 
x 1071 
0 4 x 1 0 / 1 
1 
2 
SS 
9S 
2 
1 
ад 
ix io/i 
0x10/1 
Х І 0 / І 
x l O / l 
0x1071 
Sx 1071 
X107I 
A l 
A l 
Л 2 
Л 1 
А2 
A l 
A l 
A l 
A l 
A I 
A2 
A2 
A2 
A l 
A2 
A 2 
A l 
A l 
Л 2 
A 2 
A l 
H I A phenotype 
m 1112 D R I O R I 
A2 B8 B4() D R I DRS 
A l BS BIS D R I DR4 
Л12 H7 BX D R 2 D R I 
BK B4II D R I D R u X 
A2 BX B4() D R I DRwft 
A2 BXB12 D R 4 DRS 
A4 BXB1S D R ! D R 4 
BX I )R4 D R w h 
Л2 І Ш B2I D R 4 
Л2Ч B12 B40 D R 4 D R 7 
B12 BIS DR4 
A l i B12 B27 D R 4 DRS 
A 1 0 B 1 7 B21 D R 4 
A l B12 BIS D R I DR4 
A l i B12 B l h D R 2 D R 4 
A H BIS D R I DR4 
A l B17 BIS D R I DRS 
A W BX B40 D R I D R 4 
A 1 2 B S B X D R 1 D R I 
A 1 0 B X D R 4 
'AuTG = Aurothioglucose Ή Ρ = D penicillamine I P = Ihrombocviopema 'LP - leucopenia 
itO 
Dejinilion o) drug loxutn and clinical coime 
Monitoring for toxicity included counting of 
leucocues and platelets once a week during 
the first months thereafter the interval was 
gradually prolonged Leucopema and throm-
bocvtopema were considered drug-induced if 
counts in venous blood samples lell below 2 0 
x 1071 or 120 x lO'/l. respectively on at least 
two separate consecutive dates and restora 
tion of counts was observed after stopping the 
drug 
Aurothioglucosc (SO mg ι m ) was given 
weekly up to KHK) mg and then tapered off 
1) penicillamine was prescribed in initial daily 
doses ol 2^0 mg, increments were made up to 
7M) depending on the clinical response 
Sixteen patients were symptomless and 
were managed bv stopping the drug and close 
observation as out patients The remaining S 
patients had either severe thromboevtopema 
with bleeding (patients i. 2 and *)). agranulo-
cvtosis (patient IS) or fever (patient 6), all on 
Au IG 
С ontrol groups I here were 2 patient control 
groups, one for each treatment regimen The 
first control group comprised 65 RA patients 
having received aurothioglucosc (AuTG con­
trols) The second patient control group con­
sisted of 24 patients who were part of the 
AuTG control group but who had received D-
pcniullamine as well (DP controls) In these 
patient groups drug toxicity had not occurred 
during uninterrupted treatment courses of 
minimally one year The third control group 
was a panel of 277 blood donor volunteers 
(healthy controls) 
Statistical methods Significance of the asso­
ciations in the two-by-two tables was tested by 
Fisher's exact test without correction for the 
number of antigens I he p-valucs arc repor­
ted with the Tables We refrained from cal­
culating relative risks since several tabular en­
tries were zero, which makes the calculation 
impossible unless assumptions are made 
HLA tsping Typing for HI A-Α, В, С and 
DR antigens was done with standard NIH-mi-
crolymphocytotoxicity techniques HLA-DR 
ivping was done twice with two different sets 
of reagents on enriched B-lymphocyle suspen­
sions obtained after rosettmg with AET-
trcated sheep red blood cells Sera for the de­
tection of DR1-DR10 were partly of local ori­
gin, all sera being standardized against the S"1 
International Histocompatibility Workshop 
sera f-amilv studies were not performed for 
confirmation of homozygosity if only a single 
DR antigen was detectable 
Results 
[he HLA phenotypc frequencies in RA pa­
tients with haematoloxic side effects on 
Au IG and DP are shown in Table 2 Com­
pared to RA controls an increased frequency 
was observed onlv for antigens B8 and DR4 
Although antigen DR4 was high in frequency, 
the ditterence compared to RA controls was 
not significant The DR2 antigen frequency 
Table 2 
HI Л phcnonpe frequencies in RA patients with 
hiiemntotoxic reactions (RAI) RA controls {RAL) 
and healthy controls (HC ) 
Hacmato 
toxic 
(N = 21) 
12(S8%) 
9(42%) 
2(10%) 
14(68%) 
RA controls 
(N = 65) 
16(2S%) 
11 ( И % ) 
12(18%) 
MiCiïX) 
Healthy 
controls 
(N = 277) 
62 (22%) 
64(23%) 
89(12%) 
S4 (20%) 
RAI ií RAC RAT vs HC RAC vs HC 
B8 +VC ρ <0 01 ρ <0 001 NS 
DR1 +ve ρ <0 02 ρ = 0 04 NS 
DR2 fvc NS ρ = 0 03 ρ = 0 03 
DR4 +ve NS ρ <0 001 ρ <0 001 
1(1 
labi* ? 
/ / / 1 plunoí\iH /гі'і/т'пін'\ ш RA patients with hdt'ntatotoxu rt'tuttom as\iniiiiioti with ixpc ofatlxtrse η 
action 
Phcnotype 
BS +ve 
D R 1 +VL 
UH .mcl/or DR1 f\c 
DR2 fve 
DRA tve 
I cuinpcnias (I I') rhrombocvtopenias ( 11') RA controls (RAC ) 
(N = 6) (N - 19) (N = 6S) 
•i (67%) 
4 (67%) 
h ( U M I u „ ) 
( ) ( ( ] % ) 
2(11"..) 
II ( W » ) 
S(42"„) 
ii (';s%) 
2(11"..) 
14(74",.) 
lft(2V'„) 
11(17',,) 
2(1(11%) 
12(1S"„) 
Vi («".,) 
BS +VC 
D R l f v e 
BS ,iml/or DR! +\c 
DR2 .ve 
[)R4 +ve 
I Ρ n RAC 
NS 
ρ - 0 02 
ρ = orni 
NS 
NS 
I P n RA( 
ρ <() 02 
ρ - 0 OS 
ρ = 0(11 
NS 
NS 
Table 4 
Drui* ttcpemU'iH \ of Hï A IISSIH laitons ниіі Іии'тшоіоккі[\ auriuhioiilm ose i Aul (tí and I) penutìlitmme 
(DI') 
Phcnotype AurothiogluuiM- ( A u T G ) [) p inu l la i i i in i . (DP) 
loxic AuICi controls Toxic DP controls 
(N = 9) (N - 64) (N - 14) (IN = 24) 
BS + v e S(SS%) 
D R 1 -tve S(SS%) 
BS.incl'or D R l + v e 9(1(И)%) 
І Ж 2 + v e 1 ( 1 1 % ) 
DR4 t v e 1 ( 1 1 % ) 
p < ( ) ( H l l 
p<()(H) l 
p < ( l ( K l l 
NS 
NS 
1 6 ( 2 S % ) 
11 ( 1 7 % ) 
2 0 ( 1 1 % ) 
12 (IS",,) 
V)(VS%) 
s ( 1 6 % ) 
1 ( 2 1 % ) 
6 ( 4 T „ ) 
1 ( 7 % ) 
1 2 ( 9 1 % ) 
NS 
NS 
NS 
NS 
NS 
4 ( 1 7 % ) 
1 ( 1 1 % ) 
4 ( 1 7 ' , , ) 
4 ( 1 7 % ) 
1 7 ( 7 1 % ) 
this group comprises 12 thrombocytopenias all in DR4 positive patienls NS = not significant 
was lower in both toxic and non-toxic RA pa­
tients when compared to healthy controls 
With reference to type of reaction ( Table 4) 
it appeared that all 6 leucopemas (4 on 
Au IG 2 on DP) occurred in B8- and/or D R V 
positive patients (p - ()(K)1) These antigens 
were also increased in the 19 patients with 
thrombocytopenia (7 on AuTG. 12 on DP) (p 
= 0 03) When compared to RA-controls, the 
frequencies for DR2 and D R 4 were not signi­
ficantly different from those found in the con­
trol group 
Upon analysis for type of exposure (reac­
tion to AuTG or DP, Table 4), it was observed 
that the association between AuTG-mduccd 
reactions and antigens B8 and/or D R l was 
complete (p <() 001) From these 9 B8 and/or 
D R 3 positive patients. 7 ( 7 8 % ) possessed 
both antigens, as compared to only 7 out of 20 
( 1 5 % ) B8 and/or D R l positive RA control 
Ί2 
patients Looking at the DP-mduced reac­
tions, the frequencies of B8 and DR3 antigens 
were not significantly increased There was a 
positive correlation between DR4 and OP-in-
duced hacmatotoxicity It appeared that all 12 
patients with DP-mduced thrombocytopenia 
were DR4 positive 
Ihus, haematoloxicity on AuTG seems to 
be prim,inly associated with B8 and/or DR3, 
while thromboevtopenia on DP is associated 
with DR4 
Discussion 
The present data indicate that certain Hl.A 
phenotypes are risk factors for the develop­
ment ol haematotoxic reactions to aurothio-
glucose (AuIG) and D-peniullamme (DP) in 
patients with rheumatoid arthritis (RA) All 
patients with AuTG-mduced haematotoxici-
ties were B8- and/or DR^-positive. whereas 
DR4 was present m all cases of DP-induced 
thrombocytopenia 
These observations indicate a genetic pre­
disposition in RA patients to develop haema­
totoxic reactions to AuTG and DP further-
more. this genetic predisposition may be dif­
ferent for Au'IG- and DP-mduced reactions 
In the patients with AuIG-mduced reac­
tions the strength of correlations with either 
H8 or DR3 was equal In view of the linkage 
disequilibrium that exists between these anti­
gens, the high combined occurrence in these 
patients suggests that AuTG induced hacma­
totoxicity is primarily related to the haplotype 
containing both alleles. The fact that these 
phenotypes were found in patients with 
thrombocytopenia as well as leucopcnia on 
AuTG raises the possibility that patients with 
this phenotype are at increased risk for both 
types of hacmatotoxicity. Coblin and co­
workers (Cobhn et al 1981) observed an ex­
cess of HLA-DR3 in 15 RA patients with se­
vere aurothiomalatc-induced thrombocytope­
nia, 12 being positive for this antigen They 
did not mention the frequency of the antigen 
B8 Our results on AuTG are in agreement 
with theirs on aurothiomalate, with the addi­
tion that the correlation with B8 was equally 
strong. 
I here seems to be less conformity on gold 
salt-induced leucopcnia since, m contrast with 
our results. Gran and co-workers (1983) were 
unable to demonstrate a correlation with 
I (LA antigens in RA patients with aurothio-
malate-mduced leucopemas It is not incon­
ceivable that differences in inclusion criteria 
contribute to this discrepancy By rigorous in­
clusion criteria we have tried to avoid includ­
ing possible spontaneous biological variation 
m blood cell counts m the side effect group 
I his will increase the contrast between the pa­
tients with and without side effects 
It is not yet clear in which way Hl.A anti­
gens participate in adverse reactions. In non-
RA patients with drug-induced thrombocyto­
penia on exposure to various drugs, there 
seems to be no correlation with HLA-B anti­
gens (Goebcl et al 1976) In RA patients the 
possibility remains that HLA-B8-DR3 is in­
volved in the more severe reactions to anti­
rheumatic drugs This is demonstrated by an­
other toxic reaction that sometimes compli­
cates treatment with gold salts and DP, ι e. 
proteinuria In a survey of 44 proteinuric RA 
patients we found the nephrotic syndrome, as 
compared to symptomless proteinuria, prefer­
entially m patients with HLA-DR3 (Speerstra 
et al 1983) From our data it cannot be ex­
cluded that B8-DR3 positives arc more prone 
to severe haematotoxic reactions at least on 
exposure to AuTG, since the majority re­
quired hospitalization or supportive treat­
ment In contrast with the AuTG group, this 
phenotype seems to play no important role in 
the production of haematological side effects 
of DP So far as the severity of the reactions is 
concerned, there were no differences between 
the patients with and those without B8 and 
^ 
DR3 antigens. However, a high prevalence of 
DR4 was found in this group. All patients 
with DP-induced thrombocytopenia were 
DR4 positive, of whom 25% were DR4-DR 
blank, the latter frequency being almosl twice 
as high as that in the corresponding controls. 
Although the prevalence of DR4 was high in 
the controls as well, this contrast was statis­
tically significant, indicating that patients with 
phenotype DR4 are at increased risk of devel­
oping thrombocytopenia on DP. This possibil­
ity has been proposed earlier by Dawkins and 
co-workers (Dawkins et al. 1983). 
It is conceivable that other as yet unex­
plored factors contribute to an increased risk 
as well. This possibility was demonstrated by 
Batchelor et al. (1980) in hypertensive pa­
tients with hydralazine-induced SLE: in addi­
tion to HLA-DR4, the risk of having this com­
plication was increased up to 100% if the pa­
tient was a female, over 40 years old and a 
slow acetylator. With reference to drug toxic­
ity in RA, other factors such as low titres of 
IgA (van Riel et al. 1984) and specific gold 
antibodies of the IgE class (Bretza et al. 1983) 
have been reported in connection with skin 
rashes. In these studies HLA antigens were 
not investigated. The present data on correla­
tions between HLA antigens and haemato-
toxic reactions induced by AuTG or DP await 
confirmation. In the meantime, we believe it 
possible that RA patients at increased risk for 
haematotoxic reactions can be defined by tis­
sue typing. This is so because the associations 
with HLA phenotypes in the group with 
AuTG-, as well as DP-induced reactions were 
complete. The major goal - to try to avoid 
major complications - could be achieved bet­
ter by means of intensified monitoring and 
adaption of dosage schedules in the patients at 
risk while, on the other hand, in the low risk 
patient group the frequency of these tests 
could be minimalized. This would contribute 
to a less uniform and cost-saving approach in 
antirheumatic treatment (Liang & Fries 
1976). 
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CHAPTER 5 
THE INFLUENCE OF HLA PHENOTYPES ON THE RESPONSE TO PARENTERAL GOLD IN RHEUMA­
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SUMMARY 
One-hundred and ten patients with rheumatoid arthritis (RA) were studied for 
a possible influence of HLA phenotypes on the reaction to parenteral gold in 
the first 6 months of treatment, in terms of both clinical response and tox­
icity. Frequencies of HLA B8 and DR3 were significantly increased in patients 
who responded excellently to gold treatment as compared with non-responders 
(p = 0.04 for both antigens). On the other hand, HLA DR7 was increased in 
non-responders versus excellent and moderate responders (p <0.03). Drug tox­
icity was higher in excellent than in non-responders (p = 0.04), being excep­
tionally high in male excellent responders (85°ί versus 33?ί in females , ρ 
<0.01), probably due to the increased frequency in B8 and DR3 in the excel­
lent responder group as a whole and in the excellent responder males in par­
ticular. 
We conclude that HLA antigens B8 and DR3 co-determine both toxicity and ex­
cellent clinical response to parenteral gold, whereas the presence of DR7 is 
associated with non-response. In addition, we found sex differences in reac­
tion to parenteral gold, which may be related to an increased frequency of 
HLA B8 and DR3 in male RA patients. 
1)6 
INTRODUCTION 
There is convincing evidence that gold salts are effective in rheumatoid ar-
thritis (RA) (The Cooperating Clinical Committee of the American Rheumatism 
Association 1973). However, treatment with these drugs is hampered by the 
frequent occurrence of side effects. In addition, not all RA patients respond 
favourably to gold therapy. Recent studies indicate a genetic predisposition 
to the development of gold toxicity, especially proteinuria (Wooley et al. 
1980) and thrombocytopenia (Coblyn et al. 1981,Speerstra et al. 1985). At 
present there is only scanty information on whether there is also a genetic 
predisposition to a favourable response to gold therapy. Previously we have 
reported an association between HLA DR3 and excellent clinical response, but 
numbers in that study were small (Van Riel et al. 1983). The present study 
aimed to extend these observations; therefore all patients receiving auro-
thioglucose in the past three years under the standardized conditions propos-
ed by Gottlieb (Gottlieb 1979) were studied. 
On the basis of the present results, it seems that HLA B8 and HLA DR3 positi-
vity plays a role in drug response, Patients with these particular HLA pheno-
types had a greater chance of a favourable outcome, but also an increased 
risk of toxicity in the first 6 months of treatment. On the other hand, anti-
gen DR7 seemed to increase the risk of a poor response. 
MATERIALS AND METHODS 
Selection of patients. Patients included in this study were treated at 
three departments of rheiriatic diseases in the South-Eastern part of The 
Netherlands. All patients with classical or definite rheumatoid arthritis and 
treated with aurothioglucose (AuTG) between 1980 and 1984 were included for 
clinical evaluation. Adequate evaluation was available on 110 patients of 
this cohort. 
Drug prescription and monitoring. After a test dose of 10 mg patients receiv-
ed 50 mg AuTG weekly up to the 20th week, after which the dose was reduced to 
50 mg every 2-4 weeks. Patients had a monthly check-up including a question-
naire, physical examination and venipunction for determination of ESR and 
haemoglobin. In addition, monitoring for haematological and nephrological 
side effects (leucocyte count and differential, platelet count and routine 
testing for proteinuria) was initially done weekly and, during maintenance 
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Table I. Grading of the four components of IDA. 
Grade 
1 
2 
3 
a 
Durat ion 
morning 
(mm) 
<10 
10-30 
31-120 
>120 
) o f 
S t l f f n ess 
Observer 
assessment 
very good 
f a i r 
poor 
very poor 
Hb(mmol/l) 
male 
>B.7 
8.1-8.6 
6.2-8.0 
<6.1 
female 
>7.4 
6.9-7.3 
5.3-6.8 
<5.2 
E5R(mm/h) 
0-20 
21-45 
46-80 
>B1 
therapy, at least once every 4 to 6 weeks. Patients were considered to have 
developed an adverse reaction to AuTG if any of the following signs were ob­
served: severe pruntis, rash or stomatitis, which diminished after stopping 
treatment; proteinuria exceeding 500 mg/24 h for more than two weeks; a fall 
in platelet count below 120.000/mmJ; white blood cell count less than 2000/ 
mm or an absolute polymorphonuclear count below 1500/mm . 
Evaluation of drug response. A modification of a recently published scoring 
system for patients with RA was used to evaluate response (Van Riel et al. 
1983). The four parameters of the Index of Disease Activity (IDA) and its 
gradings are shown in Table 1. The degree of improvement upon therapy in each 
patient was established by determining the percentage of improvement from 
baseline (PIDA). Patients were considered to have shown an excellent response 
if this IDA at month 6 was less than or equal to 1.25 and the PIDA was at 
least 40й. Non-responders were patients who either improved less than 10% or 
deteriorated. Moderate responders were patients not covered by the previous 
classifications. 
HLA typing. HLA typing was done with standard NIH microlymphocytotoxicity 
techniques for HLA ABC and DR antigens. DR typing was done twice with two 
different sets of reagents on enriched В lymphocyte suspensions obtained 
after rosetting with AET treated sheep red blood cells. Sera were partly of 
local origin, all sera being standardized against the 8th and 9th Internatio­
nal Histocompatibility Workshop sera. 
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Statistical analysis. Fisher's exact test and the chi square test were used 
for comparison of two proportions to assess statistical significance of da­
ta. Ρ values were not multiplied by the number of antigens tested for. 
RESULTS 
A total of 110 patients were evaluated. Ninety-one (83%) improved, of whom 34 
(31%) responded excellently and 57 (52%) moderately. The remaining 19 (17%) 
showed no significant improvement or aggravation of disease symptoms. In ac­
cordance with the literature (6), the HLA-DR4 frequency was found to be sig­
nificantly increased (57%) and the HLA-DR2 frequency significantly decreased 
(18%) in the total patient group as compared with the healthy control group 
(p <0.001 and ρ = 0.01 respectively). No statistically significant differen­
ces were found between the total patient group and the group of healthy con­
trols as regards the distribution of the other HLA antigens. 
Table II. Frequency of HLA antigens and response to aurothioglucose 
Excellent Moderate Non Controls 
responders responderá responderá 
HLA η = 34 η = 57 η = 19 η = 277 
Β8 13 (ЗВЙ)· 9 (16%) 2 (11%) 64 (23%) 
DR1 
DR2 
DR3 
DR4 
DR5 
DRw6 
DR7 
DRw8 
DRw9 
DRw10 
12 
6 
12 
18 
3 
2 
4 
1 
0 
2 
(35%) 
(18%) 
(35%)* 
(53%) 
(9%) 
(6%) 
(12%) 
(3%) 
-
(6%) 
17 
10 
9 
36 
6 
6 
4 
2 
4 
2 
(30%) 
(18%) 
(16%) 
(63%) 
(11%) 
(11%) 
(7%) 
(4%) 
(7%) 
(4%) 
4 
4 
2 
9 
(21%) 
(21%) 
(11%) 
(47%) 
(16%) 
(16%) 
(37%)** 
(5%) 
(5%) 
(16%) 
70 
89 
64 
54 
65 
73 
56 
16 
8 
2 
(25%) 
(32%) 
(23%) 
(20%) 
(24%) 
(26%) 
(20%) 
(6%) 
(3%) 
(1%) 
ρ = 0.04, excellent versus no response. 
ρ < 0.03, no response versus excellent and moderate response. 
*9 
HLA antigens and drug response (table II). 
The frequencies of antigens BB and DR3 were highest in the excellent respon-
der group and lowest in the non-responder group. The4e differences were sta-
tistically significant (p = 0.04). At the same time the frequency of antigen 
DR7 was significantly decreased in the excellent responder group as well as 
in the moderate responder group as compared with the non-responder group (p 
0.03). 
HLA-phenotype, sex, drug response and toxicity (Table III and Figure 1). 
Fourty-four patients developed toxicities, mainly skin rashes (n = 34). Of 
the 44 toxic patients 14 were HLA B8 positive (32°í versus '[b% in non-toxic 
patients, n.s.) and 14 were DR3 positive (32л versus 14S in non-toxic pa­
tients, ρ = 0.04). Patients with skin rashes showed similar differences for 
BB (3B5Í versus 9%, ρ = 0.01) and DR3 (29% versus 145Í, n.s.). The incidence of 
toxic reactions was highest in the excellent responder group and lowest in 
the non-responder group (53°í and 26% respectively; ρ = 0.04). Toxicity was 
exceptionally high in excellently responding males (85%). The difference from 
females who reacted excellently was statistically highly significant (p 
<0.01). 
No significant differences in toxicity existed between both sexes in the mo­
derate and the non-responder group. 
Table III. Side effects and response to aurothioglucose. 
side effects 
response category female patients male patients total 
Excellent responders 
(n=34) 
Moderate responders 
(n=57) 
Non-responders 
(n=19) 
7/21 (33X) 11/13 (B5Ä)* 1B/34 (53Й) 
14/37 (З Й) 7/20 (35S) 21/57 (37%) 
3/13 (23S) 2/6 (ЗЗЙ) 5/19 (26%) 
ρ <0.01 (male compared w i t h female) 
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Figure 1. Data about toxicity, degree of response, HLA-DR3 and B8 positivity 
in 110 aurothioglucose treated patients. Each symbol represents a 
patients. 
As to type of response, no statistically significant difference was found be­
tween the sexes. There was, however, a sex difference in HLA BB and DR3: from 
the total of 39 males, 12 (312S) were ΒΘ positive as compared with 12 out of 
71 female patients (M%·, n.s.); for DR3 the figures were 14 (30%) and 9 (13Й) 
(p <0.01). 
DISCUSSION 
The present data indicate that in patients with active rheumatoid arthntis-
the reaction to parenteral gold therapy, in terms of both toxicity and effec­
tiveness, is co-determined by HLA phenotypes. As for effectiveness, excel­
lent respondership was found to be associated with HLA B8 and DR3, whereas 
poor respondership was associated with DR7. The high coincidence of toxicity 
and excellent respondership found in this study, suggests that there is a 
subgroup of RA patients who have increased reactivity to gold treatment and, 
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furthermore, that these pat Lents are more frequently ΒΘ and/or DR3 positive. 
The fact that the group of excellently responding male patients showed an 
exceptionally high incidence of toxicity is most probably related to the 
higher prevalence of the latter antigens in this patient catagory. In any 
case, it cannot be concluded from these data that male sex per se represents 
an independent factor determining reaction to gold therapy in patients with 
rheumatoid arthritis. 
It is important to realize that our results concern drug effects during the 
first 6 months of treatment and that the conclusions do not necessarily apply 
to late drug manifestations. This might explain, at least in part, the dis­
crepancy between studies of drug toxicity and HLA phenotypes. Correlations 
with antigens B8 and DR3 are probably primarily restricted to drug effects 
occurring in the early phase of treatment; when late drug effects dre in­
cluded, these correlations may disappear. Support for this is found in a stu­
dy on drug-induced proteinuria previously reported by us (Speerstra et al. 
1983). In this study we found a significant correlation between early onset 
proteinuria and HLA DR3. This correlation was lost, however, when late onset 
proteinuria was included. The same may be true for dermatitis, the predomi­
nant side effect in this study, which in our patients proved to be associated 
with HLA DR3, in contrast to other reports (Dequeker et al. 19Θ4, Pdnayi et 
al. 1978). 
Only two reports have so far studied the effectiveness of gold treatment in 
relation to HLA phenotypes. In the study of Van Riel et al (Van Riel et al. 
1983), a positive correlation was found between a favourable response and DR3 
positivity. Recently this observation has been confirmed by Bensen et al 
(Bensen et al. 1984). However, 0'Duffy et al could not confirm this observa­
tion (O'Duffy et al. 1984). They reported a relationship between the absence 
of antigen A3 and the simultaneous presence of antigen DR4 and poor reponder-
ship on gold. In our study, the frequency of these particular antigens was 
not different in the various responder categories. 
To our knowledge this is the first report on sex differences in drug response 
in patients with rheumatoid arthritis. The higher prevalence of antigen DR3 
observed in the male patient category indicates that the genetic background 
differs from that of female patients leaving the possibility that drug re­
sponse and probably also certain disease manifestations may show differences 
between both sexes. A recent study has also concentrated on this aspect. 
Dequeker et al (Dequeker et al. 1984) reported an increased frequency of an­
tigen DR4 in male patients who had developed RA before age 40. In his study, 
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however, the development of toxic reactions to gold and d-penicillamine was 
not essentially different in males as compared withfemales. 
In conclusion, our data provide evidence that HLA antigens play a role in the 
reaction of patients with rheumatoid arthritis to parenteral gold therapy, 
not only in terms of toxicity, but also in terms of effectiveness of the 
drug, both being associated with HLA BB and DR3. In addition, we found that 
these antigens are more freguently found in male RA patients, which might ex-
plain the different frequency of toxicity found in our study. These observa-
tions, however, need further confirmation by other studies. 
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SUMMARY 
Two pairs of sibs with definite rheumatoid arthritis responded remarkably si­
milar to parenteral gold therapy, both in terms of toxicity and efficacy Both 
pairs proved to be HLA identical. One of the pairs possessed the HLA antigens 
ΒΘ and DR3, that have been associated with both drug toxicity and excellent 
clinical response. The other pair did not posses one of these antigens, sug­
gesting that the reaction to gold therapy in patients with rheumatoid arthr­
itis may be determined by other HLA and/or genetical factors coded for by 
chromosome 6. 
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INTRODUCTION 
Paranteral gold still is a cornerstone of drug treatment of rheumatoid arthr­
itis (RA). Disadvantages of the drug are its frequent toxicity and its inef­
fectiveness in some patients. Recently, associations with certain HLA anti­
gens have indicated that genetic factors play a role in both gold toxicity 
and effectiveness (1-4). HLA antigens involved include HLA ΒΘ and DR3 in gold 
toxicity and DR3 in excellent respondership to the drug (1,2,3). Another stu­
dy (4) found a relationship between the absence of antigen A3 and the simul­
taneous presence of antigen DR4 and bad respondership to parenteral gold. 
In the present report we describe two pairs of sibs with rheumatoid arthritis 
who responded remarkably similar to parenteral gold therapy, both in terms of 
toxicity and clinical response, one of the sib pairs doing so during two sub­
sequent courses of parenteral gold. Tissue typing showed that both pairs of 
sibs were HLA identical; whereas one pair of sibs was HLA ΒΘ and DR3 posi­
tive, the other one did not possess HLA antigens known to be associated with 
toxicity of clinical response. This observation suggests that other HLA anti­
gens and/or genetic factors coded for by chromosome 6 play a role in the 
reaction to parenteral gold and patients with rheumatoid arthritis. 
METHODS 
In the context of a large study on families with multiple cases of rheumatoid 
arthritis, we detected two sib pairs with definite rheumatoid arthritis ac­
cording to the revised ARA diagnostic criteria (5), who responded remarkably 
similar to parenteral gold therapy, i.e. aurothioglucose. Toxicity was moni­
tored by regular questionaire, physical examination, blood counts and urina­
lysis. Response to gold therapy was evaluated according to a modification of 
a recently published scoring system for patients with rheumatoid arthritis 
(3,6). Parameters used in this evaluation are the duration of morning stiff­
ness, observer assessment, hemoglobin and ESR. HLA typing was done with stan­
dard NIH microlymphocytotoxicity techniques for HLA ABC and DR antigens. Sera 
were partly of local origin, all sera being standardized against the Bth and 
9th International Histocompatibility Workshop sera. 
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Table II. Reaction to parenteral gold 
patient 
toxicity 
type 
after 
at dose (mg) 
response 
type 
after 
Hb (mmol/l)7.1 
a* 
Φ 
ESR (mm/h)25 
a 
b 
MS 3 (min)"^' 
a 
b 
doct.assessment 
sib pair I 
A 
dermatitis 
5 wk 
250 
excellent 
2 mo 
8.4 
8.1 
36 
19 
120' 
15' 
excellent 
В 
dermatitis 
3 mo 
850 
excellent 
3 mo 
7.3 
7.5 
66 
21 
120' 
0' 
excellent 
sib pair II1 
С 
dermatitis 
stomatitis 
4 mo 
1200 
moderate 
3-4 mo 
8.8 
8.1 
33 
10 
120' 
15' 
excellent 
D 
dermatitis 
8 mo 
1100 
moderate 
4 mo 
7.5 
6.5 
30 
15 
120' 
10' 
excellent 
sib pair 
С 
dermatiti 
5 mo 
500 
moderate 
6 mo 
7.9 
8.1 
59 
28 
15' 
0' 
good 
IlZ 
LS 
D 
dermatitis 
9 mo 
800 
moderate 
4 mo 
7.1 
7.1 
25 
13 
15' 
0' 
excellent 
' First treatment episode 
2 Second treatment episode 
3
 MS = morning stiffness 
* a = at the onset of therapy 
' b = at evaluation of response 
Table I. Patient Characteristics 
sex 
age at onset RA 
joint erosions 
nodules 
serology 
Rose/Waaler 
latex fixation 
ANA 
HLA haplotypes 
sib pair 
pat A 
F 
53 
+ 
-
1/64 
-
-
A10Bw21DI 
I 
pat В 
F 
54 
+ 
-
1/128 
nd 
-
Î3/A3B40I 
sib pair II 
pat С pat D 
M F 
53 72 
+ + 
1/256 
+ 
+ 
A2B7DR4/A2B18DR4 
SIB PAIRS 
All four patients had symmetrical polyarthritis. Patient characteristics and 
data on the reaction to parenteral gold are represented in table I and II re­
spectively. 
Sib pair 1 (two sisters). Patient A got rheumatoid arthritis at the age of 
53. There was no sufficient response to NSAID. At the age of 54 treatment 
with aurothioglucose was started. After only 250 mg of parenteral gold, she 
developed a skin rash predominantly round the shoulder and the elbow, neces­
sitating to stop the treatment. At the same time there were only minimal 
signs of arhntis. The skin rash disappeared in the month thereafter. Patient 
B, her elder sister, developed rheumatoid arthritis at the age of 54. Treat­
ment with NSAID and hydrochloroquine was not persistently successful. At the 
age of 58 treatment with aurothioglucose was instituted. After 850 mg of the 
drug,given in a period of three months, she developed a macular papillär 
rash, for which treatment had to be stopped. Thereafter, the skin rash gradu-
ally disappeared. At the time of the skin rash, there was no disease activity 
at all. 
Sib pair 2 (brother and sister). Patient С got rheumatoid arthritis at the 
age of 53. Initially, he had been treated with NSAID and hydroxychloroquine, 
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which was initially effective but later on not sufficient to control disease 
activity. At the age of 58 years, gold therapy was instituted. After 4 months 
he developed dermatitis at the right elbow, the nates and in the groins. 
There was a slight stomatitis. Gold was stopped. At that time there was no 
disease activity anymore. Approximately five and a half years later, gold was 
reinstituted because of a disease flare. This treatment had to be stopped af-
ter a cumulative dose of 500 mg, because of skin rashes at the ear,wrist and-
scrotal area. Clinical response was good, although some rest swelling of the 
joints was present. Patient D, his elder sister, got rheumatoid arthritis at 
the age of 71. She was initially treated with NSAIDs and hydroxychloroquine, 
without clinical effect. At the age of 72, gold therapy was started; after 
four months of treatment, there were no signs of active arthritis anymore. At 
the cumulative dose of 1100 mg she got a moderately severe dermatitis of the 
abdominal region and the back. Gold was stopped. There were no signs of dis-
ease activity at that time. Because of a flare, gold was reinstituted one and 
a half year later. After three months of therapy, there were no signs of dis-
ease activity anymore. At a total dose of BOO mg (after 9 months) she deve-
loped a dermatitis, predominantly localized at the arms and trunk, necessita-
ting to stop the treatment. At that time there was only slight disease acti-
vity. 
DISCUSSION 
This report shows a remarkably identical reaction to parenteral gold therapy 
in two sib pairs, both in terms of toxicity and favourable clinical response 
to the drug. Tissue typing showed that the sib pairs were HLA identical. 
Toxicity on parenteral gold therapy has been found in some studies to be as-
sociated with certain HLA antigens, namely HLA B8 and DR3 (2,7,8,9,10). These 
associations were predominantly found for gold-induced proteinuria (7,8) and 
thrombocytopenia (9,10). Interestingly, an association between the most fre-
quent side effect i.e. skin rash and HLA antigens has been found in only a 
few studies (2,11,12). Bardin et al (11) found an association with the haplo-
type A1 Cw7 B8 DR3 and our group has recently reported an association with 
HLA B8 and DR3 (12). It should be stressed, however, that other groups have 
been unable to find associations between HLA antigens and gold toxicity (13,-
14). 
Interestingly, the patients in the two sibships developed the same kind of 
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toxicity and in addition, showed the same favourable clinical response to the 
drug. One of the sib pairs was positive for HLA B8 and DR3, antigens, that 
have been associated with both gold toxicity (1,2,7,8,9,10,11) and excellent 
clinical response (3,12). The other sib pair, however, did not possess these 
antigens. Both patients of the latter sib pair received two courses of gold 
and at both times reacted identical to this treatment. This observation sug-
gests that other genetic factors, be it HLA and/or other genetic factors as-
sociated with chromosome 6, play a role in the reaction to parenteral gold 
therapy. 
Although suggestive, the present data of course are essentially anecdotal and 
need to be confirmed by more extensive studies. There is, however, accumula-
ting evidence that genetic factors play a role in the way patients react to 
antirheumatic drugs, both in terms of side effects and efficacy. It may 
therefore be important in case of multiple case families to take a history of 
drug toxicity and clinical response. If HLA identity proves to be of any im-
portance, HLA typing in such cases might become important in the future, es-
pecially in case of severe side effects. 
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CHAPTER 7 
COMPARISON OF THE EFFECT OF ANTIRHEUMATIC DRUGS IN FIRST DEGREE RELATIVES 
WITH RHEUMATOID ARTHRITIS 
F Speerstra, PLCM van Riel, Ρ Reekers, JP Vandenbroucke, LBA van de Putte 
Submitted for publication 
SUMMARY 
We selected 13 pairs of first degree relatives with definite or classical 
rheumatoid arthritis, who had undergone treatment with identical second line 
drugs (parenteral gold, d-pemcillamine), to look for possible concordances 
in drug effects, both in terms of toxicity and efficacy. The selected 13 
pairs, had 15 paired therapeutic episodes. Ten out of 15 paired therapeutic 
episodes were concordant for toxicity (expected 7.5); patients with a toxic 
relative developed more frequently drug toxicity than patients with non-toxic 
relatives (relative risk 1.Θ, ρ = 0.146). However, favourable respondership 
in a relative had no predictive value. Numbers in the 3 haplotype sharing ca­
tegories were too small to detect any influence of the degree of haplotype 
sharing on concordance. The only two HLA identical pairs were remarkably sim­
ilar in reaction to parenteral gold, both in terms of toxicity and efficacy. 
Studying the influence of sex on concordance showed that 4 out of 5 concor­
dances for toxicity were in sexidentical pairs, whereas 4 out of 5 concordan­
ces for non-toxicity were in sex non-identical pairs. Our data suggest that 
parenteral gold- or d-pen ι cillamine-induced toxicity in a first degree rela­
tive may be a risk factor for patients with RA to be treated with these 
drugs. 
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INTRODUCTION 
Genetic factors play not only a role in the pathogenesis of rheumatoid arthr-
itis (RA), but also seem to be involved in the way patients with RA react to 
so-called second-line drugs (1-8). These studies have been carried out in 
groups of unrelated patients with RA and have indicated associations of cer-
tain HLA antigens with drug toxicity in d-penicillamine (1,2,4,5,8) and with 
both drug toxicity (1-8) and efficacy (6,7) in parenteral gold treatment. No 
studies have been performed in relatives with RA, to look for possible simi-
larities in drug response, apparently because such a study has to deal with 
many obstacles. However, this type of information would be useful, since pa-
tients frequently want to be informed on the chance to have asimilar reaction 
to a certain type of treatment as a known relative. This is especially true, 
in case of severe drug toxicity in the latter. In the present study we report 
on pairs of first degree relatives with RA, obtained from a large study of 
families with multiple cases of RA, who had been treated with the same second 
line drug, either parenteral gold (aurothioglucose, AuTG) or d-penicillamine 
(DP). We looked for concordance in both (non)toxicity and (non)efficacy and 
for the possible influence of HLA haplotype sharing and sex identity. 
PATIENTS AND MFTHODS 
Patients. We selected one pair of patients from each multiple case family, 
using the following criteria: 
- both patients had to have definite or classical rheumatoid arthritis (9) 
- they had to have been treated with the same second-line drug 
- they had to be first degree relatives (sib-sib, parent-child) 
- availability of adequate clinical and drug therapy data. 
In case more than two cases per family were eligible, we selected pairs of 
the youngest and the eldest ones in terms of start of treatment. Selection 
was done without knowledge of the reaction to therapy and without knowing the 
results of HLA studies. In addition, sex was not a selection criterium. Using 
the above procedure, we selected 13 pairs of RA patients. Two of these pairs 
had been treated with both parenteral gold and d-pencillamine. This resulted 
in 15 paired therapeutic episodes to be studied. Of the 26 patients, 15 were 
females. Of the 13 pairs, 9 were sib-sib - and 4 parent-child pairs. 
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Drugs, dosage schedules, and toxicity monitoring. After a test dose of 10 mg 
patients received 50 mg AuTG weekly up to the 20th week, after which the dose 
was reduced to 50 mg every 2-4 weeks. D-penicillamine was given in one 250 ng 
tablet daily, and the dosage slowly raised to a maximum of 750 mg per day de­
pending on the clinical response. Patients had a monthly check up, including 
a questLonaire, physical examination and venapunction for determination of 
sedimentation rate and hemoglobin. In addition, monitoring for haematological 
and nephrological side effects (leukocyte count and differential, platelet 
count and routine testing for proteinuria) was initially done weekly and, du­
ring maintenance therapy, at least once per 4 to 6 weeks. Patients were con­
sidered to have developed an adverse reaction to AuTG or DP if any of the 
following signs were observed: severe pruntis, rash or stomatitis, which di­
minished after stopping treatment; proteinuria exceeding 500 mg/24 h for more 
than two weeks; a fall in platelet count below 120.000/mm ; white blood cell 
count less than 2000/mm or an absolute polymorphonuclear count below 1500/ 
3 
mm . 
Evaluation of drug response. A modification of a recently published scoring 
system for patients with RA (6,10) was used for evaluation of response. The 
four parameters of the index of Disease Activity (IDA) and its gradings are 
shown in Table I. The degree of improvement on therapy in each patient was 
obtained by determining the percentage of improvement from baseline. Patients 
were considered to have responded if they showed an improvement of at least 
20й within 6 months treatment. Non-responders were patients who either im­
proved less than 20% or deteriorated. 
Table I. Grading of the four components of IDA. 
Grade Duration of Observer Hb(mmol/l) ESR(mm/h) 
morning stiffness assessment 
(min) male female 
1 
2 
3 
4 
<10 
10-30 
31-120 
>120 
very good 
f a i r 
poor 
very poor 
>8.7 
Θ.1-8.6 
6 . 2 - 8 . 0 
<6.1 
>7.4 
6.9-7.3 
5.3-6.8 
<5.2 
0-20 
21-45 
46-80 
>81 
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Statistical analysis. The expected number of pairs in which both members re­
acted in a similar way (either in regard to (non)toxicity or clinical respon­
se) was calculated under the assumption of independence of these episodes. 
Chi-square statistics were applied to the two by two tables and two-sided ρ 
values were calulated. 
RFSULTS 
Data on the 26 patients (13 pairs) and their 30 therapy episodes are given in 
table II. Of the 30 therapy episodes, 22 were on aurothioglucose, and 8 on d-
pemcillamine. Of the 30 therapy episodes, 15 (50?ί) were associated with 
drug toxicity at some time during treatment, a value somewhat higher than 
that in populations of unrelated patients, i.e. 30 to 40 percent (11,12). 
Twenty-two of the 30 episodes could be classified as a (favourable) response 
to drug treatment. If the 30 therapeutic episodes had been in non-relatives, 
the following calculations can be made for the expected number of concordant 
pairs. Since 15 of the 30 patients developed toxicity, i.e. a chance of 0.5, 
the chance of 2 patients to be concordant for toxicity is 0.5 χ 0.5 = 0.25. 
Similarly the chance of concordance for non-toxicity is 0.5 χ 0.5 = 0.25. 
Therefore the total chance for concordance of (non)toxicity is 0.25 + 0.25 = 
0.5; this means an expected number of 0.5 χ 15 pairs = 7.5 concordant pairs. 
Likewise calculations can be made for the chance of concordance for response 
(= 0.5377) and for non-response (= 0.0711), leading to a total chance of con­
cordance for (non)response of 0.5377 + 0.071 = 0.6088; this means an expected 
number of 0.6088 χ 15 pairs = 9.132 concordant pairswith respect to (non)re-
sponse. 
Toxicity. Table III represents the toxicities divided into those in the 
youngest and those in the eldest ones in terms of sequence of treatment. It 
can be seen from this table that of the 6 younger patients with an elder 
first degree relative with toxicity, 5 developed also toxicity, whereas only 
4 out of 9 without a toxic relative did so. So having a toxic first degree 
relative seems to be associated with a risk for toxicity of: 5:6/4:9 r 1.8 
(chi square 2.117, ρ = 0.146). 
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TABLE II. Clinical response and toxicity in 13 pairs of first degree relatives treated with the same 
antirheumatic drug, i.e. either aurothioglucose (AuTG) or d-pemcillamine (DP) 
family, sex, age at onset drug response^) toxicity HLA haplotypes 
relationship of treatment 
I vd Wi 
1 m son 27 AuTG - - A1B8DR5/AW33B7DRw8 
2 f mother 67 AuTG + dermatitis, A1B8DR5/A9B37DRw10 
alopecia,fever 
II 
III 
IV 
V 
vd В 
1 f 
2 f 
H 
1 m 
2 f 
Key 
1 f 
2 m 
vd E 
1 f 
2 f 
sib 
sib 
sib 
sib 
sib 
sib 
mother 
daughter 
58 
54 
50 
60 
74 
59 
55 
31 
AuTG 
AuTG 
AuTG 
AuTG 
AuTG 
AuTG 
AuTG 
AuTG 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
dermatitis 
dermatitis 
-
dermatitis 
dermatitis 
polyneuropa ithy 
A10Bw21DR3/A3B40DR4 
identical 
A1B8DR1/A11B27DR1 
A3B37DRw10/A2B15DR4 
A2B7DR4/A2B18DR4 
identical 
A2B15DRw6/A1B27DR1 
A2B15DRw6/A1B8DR3 
VI Lo 
1 f mother 43 AuTG + dermatitis Aw31B5DR4/A3B18DR3 
fever 
2 f daughter 36 AuTG + dermatitis Aw31B5DR4/A9B37DR4 
VII Waa 
1 m father 53 AuTG + dermatitis A3B7DRw6/A10B27DR1 
2 m son 27 AuTG - diarrhea A2B15DR4/A10B27DR1 
proteinuria 
vin Thie 
1 f sib 
2 f sib 
42 
65 
AuTG 
AuTG 
+ 
+ 
-
dermatitis 
A9BxDR2/A2B12DR4 
A3B7DRw10/A2B12DR4 
IX 
X 
XI 
XII 
XIII 
Via 
1 m 
2 m 
Smi 
1 f 
2 f 
Ko 
1 m 
2 f 
Ja 
1 m 
2 m 
van 
1 f 
2 m 
sib 
sib 
sib 
sib 
sib 
sib 
sib 
sib 
de V 
sib 
sib 
37 
48 
(1) 
(2) 
(1) 
(2) 
(1) 
(2) 
(1) 
(2) 
36 
44 
38 
43 
38 
51 
39 
51 
52 
57 
54 
56 
AuTG 
Au Tg 
AuTG 
DP 
AuTG 
DP 
AuTG 
DP 
DP 
AuTG 
DP 
DP 
DP 
DP 
+ 
-
+ 
+ 
+ 
+ 
-
-
-
+ 
+ 
+ 
+ 
-
dermatitis 
proteinuria 
-
-
dermatitis 
-
-
-
-
-
proteinuria 
thrombocytopenia 
-
_ 
-
A2Bw22DR4/A1BBDR3 
A2Bw22DR4/A2B12DR5 
A3B15DR1/A28B40DR4 
A3B15DR1/A3B7DR2 
A3B15DR1/A3B7DR2 
A3B37DRw10/A1B8DR3 
A3B37DRw10/A2B12DR4 
A9B15DR4/A1B8DR3 
A1B8DR4/A1BBDR3 
A2B7DR2/A2B7DRw6 
A11B7DR3/A2B7DRw6 
1) + = response; - = non-response. 
Table III. Distribution of toxicity among youngest and eldest of 
first-degree relative pairs (see text). 
Toxicity in youngest Toxicity in eldest 
present absent 
present 5 4 
absent 1 5 
Looking in a somewhat different way to table III, it can be concluded that 5 
pairs were concordant for toxicities and 5 for being non-toxic. So we found 
10 concordant paired episodes in terms of toxicity or non-toxicity, whereas 
from the above mentioned calculation, it appears that 7.5 concordant paired 
episodes would have been expected. 
Response. Data in the form of a two by two table are represented in table 
IV. From this table it can be seen that patients with an elder responder re­
lative, have a chance of 8:12 to react identically themselves, whereas pa­
tients with non-response relatives, have a chance of 2:3 to react favoura­
bly. The relative risk here is therefore 1.0 (chi square = 0.000). Looking in 
a different way to table IV, it can be concluded that 9 paired episodes were 
concordant, 8 for responder and 1 for non-respondership. From the above men­
tioned considerations, we would have expected a number of 15 χ 0.6088 = 9.132 
paired concordant episodes. We conclude from these observations that type of 
response to second line drug treatment in an elder relative is not a predict­
ive factor for a patient to be treated with this drug. 
Table IV. Distribution of response among youngest and eldest 
of a first-degree relative pair (see text). 
youngest eldesL 
response non-response 
response 8 2 
non-response 4 1 
12 3 
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Influence of haplotype sharing and зех. To study the influence of haplotype 
sharing on concordance, parent-child pairs were left out, leaving 9 sib-sib 
pairs with the following haplotype status: 2 HLA-identical, 6 haplotype iden­
tical and 1 non-identical. These numbers were too small to detect any influ­
ence of the degree of haplotype sharing on concordance. The only noticable 
feature was that the two HLA identical pairs were remarkably similar in both 
respondership and toxicity. 
Studying the influence of sex on concordance showed that 4 out of 5 concor­
dances for toxicity were in sex identical pairs, whereas 4 out of 5 concor­
dances for non-toxicity were in sex non-identical pairs. No special distribu­
tion was found for concordances in (non)response. 
DISCUSSION 
Our data suggest, that first degree relatives with rheumatoid arthritis (RA) 
treated with similar second line therapy, are more frequently concordant in 
drug response in terms of toxicity or non-toxicity than would have been ex­
pected by chance. In addition, patients with a relative with a history of 
drug-toxicity, developed toxicity themselves more frequently than patients 
with non-toxic relatives. In our study favourable response in a relative had 
no predictive value. Because limitation of numbers, nothing definite could be 
said on the influence of either haplotype sharing or sex on concordancy. 
Studies as the present one may give important information both to the pa­
tient and the physician. RA has a tendency to cluster in families (13) and, 
since the number of so-called second line drugs is limited, there is a consi­
derable chance that two affected members of a multiple case family will be 
treated in the same way. In clinical practice it is not uncommon for a doctor 
to be asked by a patient with RA about the chance of developing toxicity on 
second line drugs, given the fact that a relative has developed a toxicity on 
a similar drug. 
The fact that, to our knowledge no larger studies are available on this sub­
ject, is almost certainly due to the obstacles one has to deal with, when 
facing this problem. Patients have to be collected from different centres, 
they usually have been treated with different treatment schedules and docu­
mentation often is not uniform, to name only a few obstacles. 
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We were unable to study any influence of the HLA system properly, because of 
the small number of pairs available. All that could be said is that the 
only two HLA identical sibs were remarkably similar in their reaction to drug 
therapy, both in terms of toxicity and clinical efficacy. A detailed clinical 
description of these patients has been reported elsewhere (14). Studies of 
groups of unrelated patients with rheumatoid arthritis have indicated asso­
ciations of particular HLA antigens with both toxicity (1-8) and, recently, 
clinical efficacy (6-7), indicating that the reaction to second line anti­
rheumatic drugs is influenced by genetical factors. Investigations in fami­
lies may allow for studying the influence not only of the HLA system, but al­
so of other genetic factors on reaction to drug therapy. Our data suggest 
that other genetical factors may be present, at least for the development of 
toxicity. An interesting observation was the distribution of concordances for 
(non)toxicity over the sex identical and non-identical pairs. Concordances 
for toxicity seems to cluster in the sex identical groups, whereas concordan­
ces for non-toxicity were mainly found in the sex non-identical pairs. Since 
numbers are small, these observations of course need to be confirmed. Apart 
from clinical usefulness, family studies on drug reactions may deepen our in­
sight into genetical factors and probably mechanisms operative in reaction to 
drugs. The present data suggest that this approach may be fruitful and war­
rant further studies. 
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SUMMARY AND CONCLUSIONS 
SUMMARY AND CONCLUSIONS 
So-called second line antirheumatic drugs, including parenteral gold and d-
penicillamine, are still a corner stone in the treatment of the more severe 
forms of rheumatoid arthritis (RA). The clinical use of these drugs is ham­
pered by the frequent occurrence of side effects. In addition, only part of 
the patients respond to this form of therapy. The present thesis deals with 
the possible influence of genetic factors on the reaction to second line an­
tirheumatic drugs, using the HLA system as a genetic marker system. The re­
sults of the studies presented in this thesis indicate that certain types of 
side effects of these drugs are associated with particular HLA phenotypes. In 
addition, we also found associations with HLA phenotypes and type of response 
to the drug. As far as side effects were concerned, we studied those toxici­
ties that can be quantified, i.e. proteinuria and hematotoxic side effects 
due to both parenteral gold and d-penicillamine. 
In chapter 2 we report the results of a case control study on a possible as­
sociation between HLA phenotypes and the development of proteinuria during 
aurothioglucose (AuTG) or d-penicillamine (DP) treatment in patients with 
rheumatoid arthritis. Data indicated that HLA-DR3 was markedly increased in 
the proteinuric patients as compared to non-proteinuric RA controls. In con­
trast to some studies reported previously, our data showed that HLA-DR3 posi­
tive patients were at greater risk during treatment with DP (RR 10.1, ρ = 
0.001) than during gold treatment (RR 1.7, ρ = 0.365). In this study we also 
looked for the degree of and the time of onset of proteinuria as variables. 
From these studies, it appears that the association between HLA DR3 and both 
nephrotic syndrome and early onset proteinuria was stronger compared with un­
complicated proteinuria and late onset proteinuria, respectively. Our data 
indicate that genetic factors in RA influence the development, the degree and 
the time of onset of drug induced proteinuria. In addition, they suggest that 
there may be differences in the pathogenesis of aurothioglucose- and d-peni-
cillamine-induced proteinuria. Since this study indicated differences in HLA 
phenotype associations between AuTG- and DP-induced proteinuria, we investi­
gated whether previous AuTG induced proteinuria is a risk factor for develop­
ing proteinuria during subsequent DP treatment, as stated by some authors. 
In chapter 3, we report on patients with rheumatoid arthritis, who have been 
treated with AuTG and subsequently with DP, and who developed drug induced 
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proteinuria. Of these patients 12 developed Autg-induced and 19 DP-induced 
proteinuria. Of the 12 patients with AuTG-induced proteinuria, only 2 (17%) 
developed DP-induced proteinuria, indicating only a slightly increased risk 
as compared with the overall incidence (9.3%) of this reaction in DP-treated 
patients. In addition, only a minority (2 out of 19, 10.6%) of patients with 
DP-mduced proteinuria had previous AuTG-induced proteinuria. HLA DR3 was 
present more frequently in DP-induced (50%) than in AuTG induced (21%) pro­
teinuria. These data suggest that different mechanisms may be operative in 
AuTG- and DP-induced proteinuria. A practical consequence of this finding is, 
that in our opinion, a history of previous AuTG-induced proteinuria is in­
sufficient reason to deny these patients the benefits of subsequent treatment 
with DP. 
Most frightening of all side effects due to AuTG or DP are the hematotoxic 
reactions. We studied HLA phenotype frequencies in 21 rheumatoid arthritis 
patients with hematotoxic reactions, either thrombocytopenia or leucopema, 
to AuTG or DP. Looking at the whole group of patients, antigens B8 and DR3 
were significantly increased as compared to both RA patients without hemato-
toxicities and healthy controls. These contrasts were strongest in the pa­
tients with AuTG-induced thrombocytopenia or leucopema: all patients deve­
loping either reaction to this drug, were ΘΘ- and/or DR3 positive (p <0.001), 
7 (78%) being positive for both antigens. In the patient group with DP induc­
ed reactions these antigens were also increased, but the differences were not 
significant. In the latter group, the prevalence of antigen DR4 was high, 
especially in the patient group with DP-induced thormbocytopenia, all 12 pa­
tients with this type of reaction being DR4 positive. From these studies we 
conclude that AuTG- and DP-induced hematotoxic side effects may have a diffe­
rent genetic background. These hematotoxic reactions seem to develop primari­
ly (or even exclusively) in genetically predisposed RA patients. Comparing 
these associations with those in proteinuria on AuTGand DP, one can conclude 
that even for one type of drug, the genetic factor, in this case a particular 
HLA phenotype, need not to be the same for different types of side effects. 
Another important question is whether not only drug toxicity but also type of 
clinical response is genetically co-determined. 
In chapter 5 we report data on a cohort of 110 patients with RA, who were 
studied for a possible influence of HLA phenotypes on the reaction to paren­
teral gold in the first 6 months of treatment, in terms of both clinical re-
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sponse and toxicity. The results indicated that frequencies of HLA B8 and DR3 
were significantly increased in patients who responded excellently to gold 
treatment as compared with non-responders (p = 0.04 for both antigens). On 
the other hand HLA DR7 was increased in non-responders versus excellent and 
moderate responders (p <0.03) . Interestingly, drug toxicity was higher in ex­
cellent than in non-responders (p = 0.04), being exceptionally high in male 
excellent responders (85?£ versus 33X in females, ρ - 0.019),probably due to 
the increased frequency in ΒΘ and DR3 in the ecellent responder group as a 
whole and the excellent responder males in particular. 
It appears from these data that the HLA antigens ΒΘ and DR3 who are associat­
ed with drug toxicity as shown above, also co-determine excellent clinical 
response to parenteral gold, whereas the presence of DR7 is associated with 
non-response. This is the first report of sex differences in reaction to pa­
renteral gold, showing that toxicity is higher in male patients. This finding 
is probably related to the increased frequency of HLA B8 and DR3 in the male 
male patients of the group studied. The side effects found in this study were 
mainly skin rashes (early skin rashes) and showed a significant association 
with HLA B8. 
The final part of this thesis reports studies on the reaction to either AuTG 
or DP in first degree relatives with RA treated with the same second line 
drug. Patients for these studies were obtained from a large family study pro­
ject in our department. Chapter VI deals with clinical details of 2 pairs of 
sibs with definite rheunatoid arthritis, who responded remarkably similar to 
parenteral gold therapy, both in terms of toxicity and efficacy of the drug. 
Both pairs proved to be HLA identical. One of the pairs possessed the HLA an­
tigen DR3, which has been associated with both drug toxicity and excellent 
clinical response (see above). The other pair did not possess this antigen, 
which suggests that the reaction to gold therapy in patients with rheumatoid 
arthritis may also be determined by other HLA or nearby located genetic fac­
tors. This observation initiated further studies. We managed to collect 13 
pairs of first degree relatives with identically treated rheumatoid arthritis 
and studied concordances in terms of toxicity and clinical response to drug 
treatment. These selected 13 pairs had 15 paired therapeutic episodes on 
either AuTG or DP. Whereas statistically one should have expected 7.5 concor­
dances for (non)toxicity, we found 10 concordant pairs. In addition, patients 
with a toxic relative developed more frequently drug toxicity than patients 
with a non-toxic relative (relative risk 1.8, chi square 2.117, ρ = 1.46). 
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On the other hand, favourable respondership in a relative did not seem to 
have any predictive value. We also looked for distribution of concordances 
over the three haplotype sharing categories (non, half and full HtA 
identical). Numbers, however, were too small to draw any conclusions. 
Studying the influence of sex on concordance showed thdt 4 out of 5 
concordances for toxicity were in sex identical pairs, whereas 4 out of 5 
concordances for поп-toxicity were in sex non-identical pairs. Our data 
suggest that extending these investigations might reveal interesting 
information concerning family history as a risk factor. 
Looking at HLA phenotypes as possible risk factors during treatment with au-
rothioglucose or d-penicillamine, the following can be said from our observa­
tions: 
- antigens ΒΘ and DR3: these antigens increased the risk for hematotoxic re­
actions on aurothioglucose and of proteinuria in d-pemcill amine. They are 
also associated with excellent clinical response on aurothioglucose. 
- antigen DR4: this antigen is a risk factor for the development of d-peni-
cillamine-induced thrombocytopenia. 
- Antigen DR7: this antigen is associated with non-response to aurothiogluco­
se. 
From the point of clinical use of aurothioglucose and d-penicillamine, we 
should like to state the following: 
- the results of our studies do not recommend the use of HLA typing to in­
fluence the choice of second line antirheumatic drugs, as far as aurothio­
glucose and d-penicillamine are concerned. 
- If the strong association between HLA phenotypes and hematotoxic reactions 
are confirmed by other studies, this would mean that tissue typing can 
identify among patients to be treated with aurothioglucose or d-penicilla-
mine a small group at risk and a larger group with a negligible risk for 
hematotoxicity. This opens the posibility for individualized monitoring 
schedules, leading to more frequent monitoring of the patient at risk and 
less frequent monitoring of the group of patients with minimal risk to de­
velop hematotoxicity. Since the latter group represent the larger part of 
patients to be treated, this could have a cost saving effect. 
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SAMENVATTING 
SAMENVATTING 
De zogenaamde tweedelijns antireumatica, waaronder parenteraal goud en d-pe-
nicillamine, zijn van essentieel belang bij de behandeling van de ernstiger 
vormen van reumatoide artritis (RA). Belangrijke nadelen van deze therapie 
zijn het frequent voorkomen van bijwerkingen en de kans dat het middel onvol-
doende effektief is. Dit proefschrift gaat over de mogelijke invloed van ge-
netische faktoren op de wijze waarop patiënten met RA reageren op deze behan-
deling. Bij dit onderzoek gebruikten wij HLA fenotypen, ook wel HLA antige-
nen genoemd, als genetische merkers. De resultaten van dit onderzoek wijzen 
erop, dat bepaalde bijwerkingen van bovengenoemde antireumatica geassocieerd 
zijn met bepaalde HtA fenotypen. Bovendien vonden wij dat het al of niet 
gunstig reageren op parenteraal goud, in deze studie aurothioglucose, 
eveneens mede bepaald wordt door bepaalde HLA fenotypen. Voor wat betreft de 
bijwerkingen: wij onderzochten met name die bijwerkingen, die gekwantificeerd 
kunnen worden, zoals proteinune en hematologische bijwerkingen. 
In hoofdstuk 2 worden de resultaten vermeld van een onderzoek naar de moge-
lijke associatie tussen HLA fenotypen en het ontwikkelen van proteinune, 
ontstaan tijdens behandeling met aurothioglucose of d-penicillamine. Onze ge-
gevens wijzen erop dat HLA DR3 meer voorkomt bij patiënten met Proteinurie, 
dan bij patiënten die geen proteinune ontwikkelden. Dit gold meer voor pa-
tienten, behandeld met d-penicillamine (RR 10.1, ρ = 0.001) dan voor patiën-
ten behandeld met aurothioglucose (RR 1.7, ρ = 0.365). In dit onderzoek be­
studeerden wij ook de ernst van de proteinune en het tijdstip van optreden 
als variabelen. Hieruit kwam naar voren, dat de associatie met HLA DR3 bij 
ernstige Proteinurie (nefrotisch syndroom) en vroeg optredende proteinune 
sterker was dan die met asymptomatische proteinune en later optredende Pro­
teinurie. Onze gegevens wijzen er dus op, dat genetische faktoren het ont­
staan, de ernst en het tijdstip van optreden van proteinune beïnvloeden. 
Aangezien ons onderzoek verschillen aangaf in HLA associatie tussen Proteinu-
rie t.g.v. aurothioglucose en d-penicillamine, hebben wij onderzocht of Pro-
teinurie t.g.v. aurothioglucose een nsicofaktor is voor het ontwikkelen van 
deze bijwerking op d-penicillamine, zoals door sommige onderzoekers is ge-
meld. 
Hoofdstuk 3 handelt over patiënten met RA, die werden behandeld met aurothio-
glucose en in een latere fase met d-penicillamine, en die proteinune op een 
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van deze of beide middelen ontwikkelden. Het betrof hier 12 patiënten met 
Proteinurie t.g.ν. aurot hiogluose en 19 met deze bijwerking t.g.ν. d-pemcil-
lamine. Van de 12 patiënten met proteinune tijdens aurothiog] ucose, ontwik-
kelden er slechts 2 (170o) deze bijwerking tijdens d-penicill amine behande-
ling. Deze frequentie is met veel groter dan die in een ongeselecteerde pa-
tiëntengroep behandeld met d-pemcillamine (9,3'о). Bovendien bleek slechts 
een klein gedeelte (2 van de 19, 10.6°ó) van de patiënten met Proteinurie op 
d-pemcillamine vroeger dezelfde bijwerking op aurothioglucose te hebben ge-
had. Deze gegevens suggereren, dat de ontstaanswijze van Proteinurie op auro-
thioglucose en d-pemcillamine wel eens verschillend zou kunnen zijn. Een 
praktische consequentie van ons onderzoek is dat, naar onze mening, een 
Proteinurie tijdens aurothioglucose geen reden mag zijn, de patient later een 
behandeling met d-pemcillamine te onthouden. 
Van alle bijwerkingen op aurothioglucose en d-pemcillamine zijn de hematolo-
gische neveneffekten het meest gevreesd. Wij onderzochten HLA fenotype fre-
quenties bij 21 patiënten met reumatoide artritis, die hematologische bijwer-
kingen, hetzij trombocytopenie of leucopeme, op deze antireumatica hadden 
ontwikkeld (hoofdstuk 4). Voor de groep als geheel gold dat de HLA antigenen 
BB en DR3 significant frequenter voorkwamen dan bij RA patiënten zonder hema-
tologische bijwerkingen. Dit verschil was het duidelijkst bij patiënten met 
trombocytopenie of leucopeme t.g.v. aurothioglucose. Al deze patiënten waren 
B8 en/of DR3 positief (p <0.001). Bij de patiënten met dezelfde soort bijwer-
kingen t.g.v. d-pemcillamine kwamen deze HLA antigenen ook wel frequenter 
voor, maar de verschillen waren niet significant. Opvallend in deze groep 
was, dat het antigeen DR4 zeer vaak voorkwam; dit gold met name de groep pa-
tienten met trombocytopenie, die allen DR4 positief waren. De sterke HLA as-
sociaties bij hematologische bijwerkingen geven aan, dat genetische predispo-
sitie hier een belangrijke rol speelt. Net als bij de proteinune (zie bo-
ven), valt op, dat de HLA associaties met hematologische bijwerkingen op au-
rothioglucose en d-pemcillamine duidelijk verschillen. 
Een andere belangrijke vraag is of ook het al of niet goed reageren op tweede 
lijns antireumatica beïnvloed wordt door genetische faktoren. Onderzoek, dat 
hierop betrekking heeft, wordt vermeld in hoofdstuk 5. Wij bestudeerden een 
cohort van 110 patiënten met reumatoide artritis, gedurende de eerste 6 maan-
den van de behandeling met aurothioglucose. Uit dit onderzoek kwam naar vo-
ren, dat de frequenties van HLA B8 en DR3 significant groter waren bij pa-
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tienten, die excellent reageerden op aurothioglucose, dan bij patiënten die 
m e t reageerden (non-responders) (ρ = 0.04 voor beide HLA antigenen). Daaren­
tegen kwam HLA DR7 freguenter voor bij non-responders dan bij uitstekende -
en matige responders (p <0.03). Een interessante bevinding was, dat bijwer­
kingen freguenter voorkwamen bij uitstekende, dan bij non-responders (p = 
0.04); dit was vooral het geval bij mannelijke patiënten met een uitstekende 
respons (855« tegenover 33?o bij vrouwelijke patiënten, ρ = 0.019). Dit houdt 
mogelijk verband met de verhoogde frequentie van HLA B8 en DR3 in de uitste­
kende respondergroep als geheel en de mannelijke patiënten uit deze groep in 
het bijzonder. Ons onderzoek wijst er dus op, dat de HLA antigenen B8 en DR3, 
die predisponeren tot het krijgen van bijwerkingen, ook mede bepalend zijn 
voor het uitstekend reageren op aurothioglucose, terwijl anderszijds de aan-
wezigheid van DR7 frequenter bij non-responders voorkomt. In ons onderzoek 
kon ook voor het eerst worden vastgesteld, dat er een geslachtsverschil be-
staat in de reaktie op aurothioglucose, in die zin, dat bijwerkingen frequen-
ter werden gezien bij mannelijke patiënten. Deze bevinding houdt mogelijk 
verband met de toegenomen frequentie van HLA B8 en DR3 bij deze groep. 
Het laatste deel van dit proefschrift betreft onderzoek naar de overeenkoms-
ten en verschillen in reaktie op behandeling met hetzelfde tweedelijns anti-
reumaticum, aurothioglucose of d-penicillamine bij eerste-graads verwanten 
met RA. Voor deze studies konden wij patiënten selecteren uit een groot fami-
liestudieprojekt. In hoofdstuk 6 beschrijven wij de klinische gegevens van 2 
paren eerste-graads verwanten met RA, die opmerkelijk uniform reageerden op 
aurothioglucose, zowel wat betreft de bijwerkingen als de effektiviteit van 
het geneesmiddel. Het bleek dat beide paren HLA identiek waren. Bij één paar 
konden het HLA antigen DR3 worden aangetoond, een fenotype, dat predisponeert 
voor zowel bijwerkingen op als effektiviteit van aurothioglucose (zie bo-
ven). Het andere paar was negatief voor dit antigen, hetgeen suggereert, dat 
de reaktie op aurothioglucose bij patiënten met RA ook nog door andere HLA of 
nabij gelegen genetische faktoren wordt bepaald. Deze waarneming vormde de 
aanleiding tot verdere studies. Wij waren in de gelegenheid 13 paren van eer-
ste-graads verwanten op te sporen, die met hetzelfde tweedelijns antireumati-
cum behandeld waren. Bij deze paren bestudeerden wij de aan- of afwezigheid 
van concordanties, voor wat betreft het ontwikkelen van bijwerkingen en voor 
de effektiviteit van de behandeling. Bij deze 13 paren konden in het geheel 
15 gepaarde therapeutische episoden worden bestudeerd, hetzij op aurothioglu-
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cose of d-penicillamine. Op statistische gronden zou men bij deze 15 gepaarde 
waarnemingen 7.5 concordanties voor de aan- of afwezigheid van bijwerkingen 
hebben verwacht; het aantal gevonden concordanties was echter groter, 
namelijk 10. Verder bleek dat de freguentie van bijwerkingen groter was bij 
patiënten met een familielid, die bijwerkingen had gehad op hetzelfde middel, 
dan bij patiënten met een familielid, die geen bijwerkingen had gehad (RR 
1.8, chi quadraat 2.117, ρ = 1.46). Een goede reaktie op goud of d-peni-
cillamine bij een familielid bleek echter geen voorspellende waarde te heb­
ben. Gezien het kleine aantal waarnemingen, kon geen uitspraak worden gedaan 
over de invloed van HLA haplotype sharing op de reaktie op de betreffende ge­
neesmiddelen. Bij bestudering van de invloed van geslachtsidenticiteit op 
concordantie bleek, dat 4 van de 5 concordanties voor bijwerkingen werden 
aangetroffen bij geslachts identieke paren, terwijl 4 van de 5 concordanties 
voor de afwezigheid van bijwerkingen aanwezig waren in niet geslachtsidentie­
ke paren. Onze waarnemingen suggereren, dat een gedetailleerde anamnese van 
de reaktie op tweedelijns antireumatica bij eerste-graads verwanten het pers­
pectief biedt, in de toekomst de kennis betreffende familiair bepaalde fakto-
ren op dit gebied uit te breiden. 
Over HLA fenotypen als mogelijke nsicofaktoren bij aurothioglucose - en 
d-penicili amine behandeling, kan het volgende gezegd worden: 
- de antigenen ΒΘ en DR3 verhogen het risico op hematologische bijwerkingen 
bij behandeling met aurothioglucose en op de proteinune bij behandeling 
met d-pemcillamine. Anderszijds zijn deze antigenen ook geassocieerd met 
een goede klinische respons op aurothioglucose. 
- antigeen DR4 verhoogt het risico op trombocytopenie tijdens behandeling met 
d-pemcillamine. 
- antigeen DR7 vergroot de kans op een slechte respons op behandeling met 
aurothioglucose. 
Uit het oogpunt van praktische toepasbaarheid zouden wij het volgende willen 
zeggen: 
- op basis van onze resultaten kan HLA typering niet worden aanbevolen als 
mede bepalende faktor b ij de keuze tussen aurothioglucose en d-penicillami­
ne. 
- de sterke associatie tussen bepaalde HLA fenotypen en het optreden van he­
matologische bijwerkingen, maakt verder onderzoek zinvol. Wanneer deze as-
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sociaties inderdaad bevestigd kunnen worden, dan zou dit betekenen, dat 
middels HLA typering, een kleine risico dragende groep onderscheiden kan 
worden van een grote groep patiënten met een vrijwel verwaarloosbaar risico 
voor het krijgen van hematologische bijwerkingen. Dit kan van praktisch nut 
zijn, omdat controleschema's dan meer geïndividualiseerd zouden kunnen wor-
den. Dit kan lelden tot meer adequate therapiecontrole en bovendien tot een 
aanzienlijke kostenbesparing. 
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ADDENDUM 
MULTIPLE CASE FAMILY PEDIGREES 

s y 11Ь о 1 s u s e d ¡ η t h e p e d i g r e e s 
O.D 
36 
unaffected female/male 
affected female/male 
person with a history of po1 y arth ra 1 g i a s , 
normal physical and radiological findings 
calendar age at the end of the follow up 
interview and examination performed 
(end foilow up) 
0 
IgM rheumatoid factor positive 
decea sed 
proband 
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family vd Wi 
age of onset 
disease course 
treatment 
son 
21 
seropositive polyarthritis 
during 14 years 
parenteral gold (2 courses) 
d-penicillamine 
mother 
5Θ 
seropositive polyarthritis 
during θ years 
parenteral gold 
radiology erosions of interphalangeal few erosions of mcp's 
joints, mcp's and wrists; and wrists 
destruction of one hip 
end follow up: 
a r t i c u l a r f i n d i n g s s u b l u x a t i o n o f m c p ' s , u l n a r no d e f o r m i t i e s 
d r i f t ; d e f o r m i t i e s o f f e e t ; normal f u n c t i o n s 
l i m i t e d f u n c t i o n o f hands, 
w r i s t s and one h i p 
e x t r a - a r t i c u l a r f i n d i n g s nodules no 
HLA phenotypea A1Aw33B7B8DR5DRwB A1A9B37B8DR5DRw10 
Ui 
.E-
Pedigree offamily ν d В 
SL 62 
-0 
59 55 43 
α, #'2 α - · ; p; a/c a/d b/d ^ a /d b/c 
Haplotype a.AIO Bw 21 DR 3 
b A2 B17 DR7 
с A2 B15 DR4 
d A3 B¿,0DR¿. 
family vd В 
pedigree number 
age of onset 
2 
53 
4 
52 
disease course active polyarthritis 
during 9 years 
polyarthritis 
during 4 years 
treatment parenteral gold 
d-penicil lamme, azathiopnne 
and corticosteroids; knee 
arhroplasty 
parenteral gold, 
hydroxychloroguine 
radiology erosions of interphalangeal 
joints, mcp's, mtp's, wrists, 
elbows 
normal 
end follow up: 
articular findings active polyarthritis; 
limited motion of 
shoulders, elbows and 
hands 
mild prolifrative 
synovitis of mcp's, 
limited motion of 
wrists and elbows 
extra-articular finding nodules nodules 
ON 
Pedigree of family H 
jzf-
71 67 62 58 
-0 
55 53 ¿8 
è', i; ¿з a .α л ft α »; О α ös-p« 
a/c a/d b/c ^ Б ^ а/с a/c 
Haplotype а A3 B37 DRwlO 
b Al B8 DR1 
с A2 B15DRZ, 
d A11 B27DR1 
a/c a/d 
family H 
pedigree number 
age of onset 
1 
50 
2 
60 
6 
48 
7 
51 
disease course active disease 
during 20 years 
mild polyarthritis 
during 7 years 
mild polyarthritis 
during 7 years, 
pleurisy 
arthralgias 
(symmetrical) 
during 2 years 
treatment hydroxychloroquine 
parenteral gold 
corticosteroids 
2 knee arthro-
plasties 
parenteral gold hydroxychloroquine 
parenteral gold 
d-penicillamine 
no medication 
radiology extensive erosions 
in hands, wrists, 
elbows, shoulders 
and feet; cervical 
subluxation 
normal few erosions of 
mcp's 
normal 
end follow up: 
ar t icu lar f indings severe deformities 
and impaired func-
t ions of a l l pe r i -
pheral j o i n t s 
ext ra-ar t icu lar f indings nodules 
mild synovi t is of 
wr is ts , normal 
functions, no 
deformities 
no active j o i n t s , 
normal functions 
extensive nodules, 
pleurisy 
normal 

family Key 
age of onset 
disease course 
sister 
72 
seropositive polyarthritis 
during 6 years 
brother 
53 
seronegative polyarthritis 
during 7 years 
treatment hydroxychloroquine hydroxychloroquine 
parenteral gold parenteral gold 
(2 courses) (2 courses) 
radiology erosions of wrists and erosions of wrists, pip's 
mtp's; coxarthrosis elbow 
and gonarthrosis 
end follow up: 
a r t i c u l a r f i n d i n g s no disease a c t i v i t y moderate disease a c t i v i t y 
a r t h r i t i s o f w r i s t s and 
rncp's 
e x t r a - a r t i c u l a r f i n d i n g s no no 
HtA phenotypes A2B7DR4/A2B18DR4 A2B7DR4/A2B18DR4 
о 
о 
II 
Pedigree of family van der E 
66 
'b 
32 
<д 
60 
nt 
Haplotype a·. AI B8 DR3 
b A28Bw22DRZ, 
с: A2 B15DRw6 
d Al B27DR1 
family vd E 
pedigree number 
age of onset 
1.2 
54 
II.1 
2B 
disease course polyarthritis during 21 
years with cervical in-
volvement; Hodgkin's disease 
polyarthritis during 5 
years of wrists, mtp's and 
hips 
treatment parenteral gold parenteral gold, 
d-penicillamine 
arthroplasty of one hip 
radiology erosions of mcp's and wrists; 
severe subluxation of atlanto-
axial joint with fracture of 
the dens 
coxitis; bilateral sacro-
ilntis; erosions of atlanto-
axial joint 
end f o l l o w up: 
a r t i c u l a r f i n d i n g s l i m i t e d motions o f w r i s t s 
p r o l i f e r a t i v e synov ia l 
s w e l l i n g o f mcp's 
m i l d s y n o v i t i s o f pe r i phe ra l 
j o i n t s , l i m i t e d p a i n f u l mot ion 
o f h i p , back and c e r v i c a l spine 
e x t r a a r t i c u l a r f i n d i n g s no no 
Pedigree of family Lo 
0-
-0 0-
78 6Θ 
-0 
70 
Ι Φ, 02 03 0, 05 ih 0 7 JZ8 0 9 Ο,ο ·'. 
a/b nt % nl e/f u/b 
37 31 
' α , 
'1 
Haplotype a Aw31 B5 DR4 
b A3 BI8DR3 
с A9 B37DR4 
d •> 
Phenotype e/f A2 All B7 Bw22 DR1 DR2 
1 5 a n d l l 2 typel diabetes mellitus 
family Lo 
pedigree number 
age of onset 
1.1 
56 
1.6 
44 
1.11 
45 
II.1 
23 
disease course longstanding 
active 
polyarthritis 
longstanding 
active 
disease 
25 years of 
active poly-
arthritis 
13 years of 
active polyarthr-
itis 
treatment hydroxychloroquine, 
corticosteroids, 
cyclophosphamide 
parenteral gold, 
(2 courses), 
corticosteroids, 
synovectomy 
hydroxychlo-
roquine 
hydroxychloro-
quine, parenteral 
gold (2 courses), 
d-penici11 amine 
azathiopnne 
radiology erosions in inter-
phalangeal joints, 
mcp's and mtp's 
erosions in pip's 
mcp's, mtp's and 
wrists 
erosions in 
mcp's and wrists 
extensive erosions 
in mcp's, wrists, 
mtp's, shoulders 
and knees 
follow up: 
articular findings no disease activity, 
deformities of 
hands and feet; 
impaired functions 
of hands 
no disease acti-
vity, deformities 
of hands and feet; 
impaired functions 
no disease acti-
vity, ulnar drift; 
limited motions 
of wrists 
active synovitis 
of mcp's, wrists 
and knees 
extra-articular findings no 
pedigree of family Waa 
ΠΙ 
50 
Ъ. 
™ 1 a/b 
LH Д5 
72 
Ά 
c / d ' 
Lb 33 
II D, D 
a /d a/d 
21 18 
A α, , 
e
 /f b /c 
1Д 
3/c 
Ö 
д/
е 
J/f 3/e 
Haplotype a A3 B7 DRw 6 
b-AI0B27DR1 
с · A2B15 DRA 
d Aw32B27DR1 
e A 2 8 B w 3 5 D R w 8 
f A 2 B 1 2 D R ^ 
family Waa 
pedigree number 
age of onset 
1.1 
52 
II.5 
26 
III.2 
20 
III.3 
θ 
disease course longstanding 
polyarthritis 
six years of 
active poly-
arhntis 
stiffness and 
pain of the 
axial skeleton 
six months of 
recurrent fever 
with polyarthr­
itis 
treatment parenteral gold 
(2 courses), corti­
costeroids; knee 
arthroplasty 
parenteral gold (2 
(2 courses),cortico­
steroids, d-penicilla-
mine, azathioprine 
salicylates 
radiology erosions in mcp's, 
wrists, knee and 
mtp's 
extensive erosions 
p i p ' s , mcp's, mtp's 
schoulder, knees; 
at lanto-axia l insta­
b i l i t y 
b i l a t e r a l 
sacroi l l i t i s 
not done 
end follow up: 
a r t i c u l a r findings 
ext ra-ar t icu lar f indings 
no disease a c t i v i t y , 
deformities of hands, 
impaired function 
active disease; 
impaired function of 
hands and knees 
nodules 
signs of axial 
arthritis 
normal 
Pedigree of family Thie 
JZf-
68 
-0 
65 63 62 61 59 S-7 56 54 52 50 48 47 44 
), Ch 0i · ' • О б 0 7 De · ' · , ο Ο π 0-2 Ói3 D u Dis О 
, \ a'd η* a /d ''θ b d b/d % "'с 4 % \ a'c ''с 
laplotype a A3 B7 DRw 10 
b A9 Bx DR2 
с A2 B15DR¿ 
d A2 B12DR4 
fanily Thie 
pedigree nunber 
IQ 11 15 
age of onset 50 54 no data 45 
available 
59 53 36 
disease course polyarthritis 
during 5 
years, followed 
by complete 
remission 
polyarthritis 
during 11 
years 
polyarthritis 
during 5 years 
followed by a 
remission of 
10 years 
years 
recent onset 
of poly-
arthntia 
recent onset 
of poly-
arthralgias 
polyarthritis 
during 6 years 
followed by 
complete remssion 
treatment hydroxychlo-
roquine 
hydroxychloro-
quine! parenteral 
gold (2 courses) 
corticosteroids 
hydroxychloro-
quine, parenteral 
gold (2 courses) 
analgesics analgesics parenteral gold 
radiology not done erosions in mcp's, 
mtp's and wrists 
erosions in mcp's 
mtp's and wrists 
normal normal normal 
end follow up: 
articular findings normal 
extra-articular 
findings no 
active polyarthr-
itis; deformities 
and impaired func-
tion of hands 
nodules 
normal mild poly- joint tender-
arthntis, ness, no 
normal fune- evident swel-
tions ling, normal 
functions 
armai 
Pedigree of family Via 
0-T-0 
65 61 58 56 49 
xTi О о, a/c % a/c a/d a/d 
Haplotype a A2 Bw22 DRA 
b Al B8 DR3 
с A2 B12DR5 
d A1 B8 DR3 
family Via 
pedigree number 
age of onset 46 29 
disease course active polyarthritis during 
21 years 
polyarthritis during 4 years 
followed by complete remission 
t reatment pa ren te ra l g o l d , c o r t i c o s t e r o i d s 
d - p e m c i l l a m i n e , azath iopr i ne , 
cyclophosphamide; 
knee a r t h r o p l a s t y 
hydroxychloroqu i ne , 
paren tera l gold 
radiology extensive erosions of peripheral 
joints including shoulders and 
hips; atlanto-axial subluxation 
normal 
end follow up: 
articular findings 
extra-articular findings 
active polyarthritis with 
marked residual damage 
nodules, vasculitis, Felty's 
syndrome 
normal 
Pedigree of family Smi 
& 
-0 
86 
I Д 02 02 04 4 jZ6 jay À ¿Г 
61 5Θ 55 49 
II 
-АДі 
¿3 
б, özjfc ê; os ρ, 
7c ЧУ u/d /с nt "ld 
Haplotype a A l В8 DR3 
b A3B15DR1 
с A3 B7 DR2 
d A28BiODR¿, 
Phenotypee/f A l A3B27 B8 DRl DR3 
family Smi 
pedigree nimber 
age of onset 
1.11 
45 
II.3 
28 
II.4 
45 
disease course longstanding poly-
arthritis of hands, 
feet, knees 
longstanding poly-
arthritis of 
peripheral joints 
polyarthritis 
during 5 years 
treatment no treatment hydroxychloroquine, 
parenteral gold, 
d-penicillamine 
parenteral gold, 
d-pen ic i l l amine 
radiology not done extensive erosions 
of interphalangeal 
j o i n t s , mcp's, 
mtps's and wrists 
few erosions of 
feet , mild instabi -
l i t y of at lanto-
axial j o i n t 
end fol low-up: 
ar t icu lar f indings 
ext ra-ar t icu lar f indings 
active synovit is 
of knees; deformities 
of hands and feet 
no disease a c t i v i t y ; 
deformities of hands, 
impaired function 
nodules 
no disease activity 
normal function of 
hands, subluxation 
of mtp's 
Pedigree of family Ko 
/с u/c u/d u/d 
Haplotype a A3B37DRw10 
b AU Bw22DRw6 
с AI B8 DR3 
d A2 B12DR4 
family Ko 
pedigree number 
age of onset 
3 
47 
5 
53 
6 
49 
disease course progressive disease 
during 12 years, leading 
to destruction of all 
peripheral joints; severe 
cervical involvement 
polyarthritis 
during 3 years 
polyarthritis 
during 3 years 
treatment parenteral gold (2 courses) 
d-penicillamine, cortico-
steroids; arthroplasties knee, 
hip, 2 elbows; cervical spon-, 
dylodesis 
parenteral gold hydroxychloroquine 
parenteral gold 
d-penicillamine 
radiology destruction of all peripheral 
joints; atlanto-axial 
involvement 
one erosion few erosions in 
mtp 's 
end follow up: 
articular findings severe disabi l i ty; 
s t i l l active disease 
no disease act ivi ty; 
normal functions 
no disease activity 
normal functions 
extra-articular findings nodules, pleurisy 
Pedigree of family Ja 
79 76 75 77 
0 - 1 - 0 
» Û, OnrÖs О г р Й Ó6 Ö7 Й 
I ! 
Рз i 
-00 П 9 LJlO 
"/с 
'/г ' а / е а ( г а/е * 
Haplotype a ΑΙ Ββ OR« 
Ь А2 B1SDR6 
с А2 BIS DRÍ 
d A9 BIS ОНА 
e Α Ι β β OR3 
f Al B8 DR7 
g А 2 В!7 DR7 
family Ja 
pedigree number 
age of onset 
II.1 
33 
II.2 
31 
II.6 
28 
disease course polyarthritis during mild polyarthritis chronically active 
12 years during В years followed polyarthritis, 
by remission, psoriasis 
Capi an's syndrome 
treatment parenteral gold d-penicillamine d-penicillamine 
d-penicillamine 
radiology erosions of pip's, mcp's few erosions in wrists erosions in mcp's, 
mtp's, wrists, shoulders mtp's and wrists 
end follow up: 
articular findings active polyarthritis, joint tenderness, no active synovitis 
ulnar drift swellings, no deformities, mcp's, one elbow, 
normal functions one knee 
extra-articular findings nodules 
π 
Pedigree of family van deV 
% TU 
W 1 ^ 2 
% n/b 
¿6 uu до 
-о, 
39 38 36 
Ь / с 2 Х а / с 3 b/c¿ b /d5 a/d 
Haplotype a A2B7 DR2 
b All B7 DR3 
с A2 B7 DRw6 
d A3Bw35DR1 
family van de V 
pedigree number 
age of onset 
1.1 
65 
II.2 
38 
II.3 
33 
disease course polyarthritis during 9 active polyarthritis mild polyarthritis 
years during 6 years followed by complete 
remission 
treatment analgesics parenteral gold, d-penicillamine 
d-penic illamine, 
corticosteroids 
radiology few erosions in hand extensive erosions of few erosions in wrists 
and feet mcps's, mtp's and wrists 
end follow up: 
articular findings mild synovitis of 2 ip's, active polyarthritis, normal 
normal function deformities of hands, 
limited motion of wrists 
extra articular findings no nodules no 

LEVENSLOOP 
De schrijver van dit proefschrift werd op 21 juli 1940 geboren te Haskerdij-
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Na een opleiding tot onderwijzer en vervulling van de militaire dienstplicht, 
werd in 1965 het diploma HBS-B gehaald aan de Rijks HBS te Sneek. 
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STELLINGEN 
I 
De reactie op langwerkende antireumatica bij patiënten met 
reumatoïde arthritis wordt medebepaald door HLA antigenen. 
II 
De sterke associaties tussen bepaalde HLA antigenen en 
haematologische bijwerkingen op goud en d-penicillamine 
wekken de verwachting dat weefseltypering in de toekomst een 
kostenbesparende factor kan worden in de behandeling van 
reumatoïde arthritis. 
Ill 
De HLA antigenen Βθ - DR3 verhogen niet alleen het risico 
op bijwerkingen maar beïnvloeden tevens het tijdstip waarop 
en de mate waarin de reactie optreedt. 
IV 
De observatie dat de HLA antigenen B8 - DR3 wèl een rol 
spelen bij het ontstaan van Proteinurie op d-penicillamine en 
niet bij Proteinurie op goud kan betekenen dat de Pathogenese 
van deze reactie op beide middelen verschilt. 
V 
Bij vergelijking van HLA associaties tussen identieke reacties 
op goud en d-penicillamine moet rekening gehouden worden met 
het relatief hoge aantal vroege uitvallers als gevolg van 
dermatitis tijdens goudbehandeling. 
VI 
De hogere frequentie van de HLA antigenen B8 - DR3 in de 
mannelijke patiëntengroep met reumatoïde arthritis maakt het 
zinvol om in de toekomst bij HLA studies geslachtsspecificatie 
te betrekken. 
VII 
Het feit dat bepaalde extra-articulaire manifestaties bij 
reumatolde arthritis sterk geassocieerd zijn met de HLA anti-
genen B8 - DR3 en DR4 kan er op wijzen dat het risico op een 
slechtere lange termijnprognose bij patiënten met deze pheno-
typen verhoogd is. 
Dinant et al: Arthritis Rheum 1980, 1336 
Cunningham et al: Reumatol Int 1982,2: 137-139 
Vili 
HLA haplotype sharingstudies bij eerstegraads verwanten met 
reumatoîde arthritis hebben tot nu toe geen verheldering ge-
bracht omtrent de invloed van genetische factoren op het 
ontstaan van deze ziekte. 
o.a. Kahn et al: Tissue Antigens 1983:22, 182-185 
IX 
Het lijkt zinvol om de familiegegevens van patiënten met 
reumatolde arthritis bij wie behandeling met goud of 
d-penicillamine wordt overwogen, uit te breiden met informatie 
over de reactie op deze middelen bij eerstegraads verwanten. 
X 
De overeenkomsten in klinisch-immunologische manifestaties 
tussen lepra en reumatolde arthritis zouden verder in betekenis 
winnen indien deze terug te voeren zouden zijn tot een gemeen-
schappelijke genetische basis. 
Panayi : Ann Rheum Dis 1982: 41, 102-103 
van Eden et al : Human Immunol 1982: 4, 343-350 
XI 
Weefseltypering als diagnostisch hulpmiddel bij reumatolde 
arthritis dient ontraden te worden. 
XII 
In de totale kosten van de behandeling met intramusculair goud 
is de goudprijs een te verwaarlozen factor. 
Liang et al: 3 Rheumatol 1976: 5,241-243 
XIII 
Mannelijke patiënten met reumatoide arthritis roken méér en 
hebben daardoor waarschijnlijk een verhoogde kans op het krijgen 
van longkanker. 
eigen waarneming 
XIV 
De aanvankelijke vrees dat de introductie van azathioprine bij de 
behandeling van reumatoide arthritis zou leiden tot een verhoogd 
risico op lymforeticulaire maligniteiten is tot op heden door retro-
spectief onderzoek niet bewaarheid. 
o.a. eigen waarneming 
XV 
Hefprednisolonkuurtje" zoals bij exacerbatie van asthmatische 
bronchitis niet ongebruikelijk is, moet bij opvlamming van chronische 
arthritis ontraden worden. 
XVI 
Bij de diagnostiek van gewrichtsziekten zijn klinische symptomen 
belangrijker dan de aan- of afwezigheid van serologische afwijkingen. 
XVII 
In de "top tien" van serologische bepalingen bij reumatische 
ziekten dient de AST van de eerste- naar de laatste plaats te 
zakken of te verdwijnen. 
Nijmegen, 18 december 1985 F.Speerstra 



